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_UMMARY
J
A new method of introducing the OXONE ® Monopersulfate Compound for urine pretreat
into a two-phase urine/air flow stream has been successfully tested and evaluated. The
feasibility of this innovative method has been established for purposes of providing a
simple, convenient, and safe method of handling a chemical pretreat required for urine
processing in a microgravity space environment. Also, the Oxone portion of the urine
pretreat has demonstrated the following advantages during real time collection of 750
pounds of urine in a Space Station design two-phase urine Fan/Separator:
• Eliminated urine precipitate buildup on internal hardware and plumbing.
• Minimized odor from collected urine.
• Virtually eliminated airborne bacteria.
The urine pretreat, as presently defned for the Space Station program for proper
downstream processing of urine, is a two-part chemical treatment of 5.0 grams of
Oxone and 2.3 ml of H2SO 4 per liter of urine. This study program and test
demonstrated only the addition of the proper ratio of Oxone into the urine collection
system upstream of the Fan/Separator.
This program was divided in three major tasks: (1) A trade study, to define and
recommend the type of Oxone injection method to pursue further, (2) The design and
fabrication of the selected metho d, and (3) A test program using high fidelity hardware
and fresh urine to demonstrate the method feasibility.
The trade study was conducted which included defining several methods for injecting
Oxone in different forms into a urine system. Oxone was considered in a liquid, solid,
paste and powered form. The trade study and the resulting recommendation were
presented at a trade study review held at Hamilton Standard on 24-25 October 94.
Representatives from NASAJMSFC, ION, Boeing, and Hamilton Standard/Huntsville
were in attendance. An agreement was reached at the meeting to continue the solid
tablet in a bag concept which included a series of tablets suspended in the urine/air
flow stream. These Oxone tablets would slowly dissolve at a controlled rate providing
the proper concentration in the collected urine.
To implement the solid tablet in a bag approach, a design concept was completed with
prototype drawings of the complete urine pretreat prefilter assembly.. A successful
fabrication technique was developed for retaining the Oxone tablets in a fabric casing
attached to the end of the existing Space Station Waste Collection System urine
prefilter assembly. The final pretreat prefilter configuration held sufficient Oxone in a
tablet form to allow normal scheduled daily (or twice daily) change out of the urine filter
depending on the use rate of the Space Station urine collection system.
Theactual tests to prove the concept were conducted using the Urine Fan/Separator
assembly that was originally used in the STS-52 Design Test Objective (DTO) urinal
assembly. The Fan/Separator was installed into a portable urine collection test rig
assembly that was positioned in a men's bathroom at Hamilton Standard for real time
collection of urine. Urine collection continued over a 2-month period with a total of 40
batches of urine collected. Each batch consisted of approximately one day of urine
collection with a fresh pretreat prefilter installed at the beginning of the day. Based on a
mass balance of urine collected and Oxone tablets used, an average pretreatment ratio
of 5.2 grams of Oxone per liter was obtained by the controlled dissolution rate method
of dispensing pretreat. This meets the test program goal of a minimum average of 5.0
g per liter. Also, a post test teardown of the test hardware including the urine separator
and downstream urine check valve showed that Oxone alone does an excellent job of
eliminating undesirable urine participates in the system. The average pH maintained in
the collection reservoir was about 4 1/2.
Other related tests were conducted to demonstrate the actual minimum ratio of Oxone
to urine that will control microbial growth. The results of this test indicated that at 3.0
gm/I there was limited control and above 4.0 gm/I microbial growth was prevented over
7 days. Also, a microbial air sampling test of the Urinal Fan/Separator 10 cfm air
entrainment flow indicated that sample points within the urine collection system and at
the outlet did not contain microbes over the detection limits of 12 CFU per M 3. Air
samples at the urine funnel showed that men's bathroom air entering the system was
as high as 193 CFU per M 3.
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INTRODUCTION
There are several problems and considerations for the proper collection, storage and
processing of urine in a microgravity environment foi" long duration manned space craft
missions such as the Space Station. Urine processing for water reclamation usually
requires the addition of chemical to fix the urea, provide microbial control, and minimize
urine participate deposits. Also, since there is minimal use of flush water, the additive
chemicals are required to eliminate participate deposits in equipment and plumbing
which can cause premature failure of hardware and systems. Since the original
conception of Space Station system layout the urine pretreat chemical additive has
been defined as oxidizer of Potassium Monopersulfate Compound (Oxone) and a
concentrated solution of Sulfuric Acid (H2SO4). The present requirements for
concentration ratios with urine is 5.0 grams of Oxone per liter of urine and 2.3 ml of
H2SO 4 per liter of urine. These ratios are driven by the downstream urine processing
system to fix the urea and eliminate urine precipitates. These pretreat chemicals have
been considered to be introduced at various points in the urine collection and
processing system. Considerations such as crew safety, ease of handling, envelope
volume, interface, and maintenance all enter into the decisions. The present system
approach is to introduce the Oxone as a mixed solution of H20 and Oxone powder
upstream of the urine separator and inject a concentrated solution of H2SO 4 directly into
the urine outlet line downstream of the urine separator. Part of the decision to
introduce only the Oxone upstream of the separator was to minimize the potential
hazard of H2SO4 injection in the proximity of urine collection from the body. Also, it was
established that injection of Oxone alone upstream of the separator was sufficient
pretreat to keep the urine collection, separator and associated hardware and plumbing
clean. It is obvious from the results of Shuttle STS-65 post flight urine separator
hardware examination that collection of urine with no pretreat protection can cause
serious quantities of urine deposits to accumulate on various surfaces. Figure 1 shows
the Shuttle EDO WCS urine separator inlet housing after a 14-day STS-65 mission with
only about 100 Kg (220 Ibs) of urine collected. Figure 2 shows the end of the 0.118
inch internal diameter pitot tube almost completely plugged with foreign debris and
urine deposits.
Previous testing at Hamilton Standard with liquid Oxone injection systems have already
demonstrated that Oxone alone injected upstream of a urine separator will provide
sufficient pretreatment to keep the separator, plumbing and downstream hardware (i.e.,
check valves, disconnects and plumbing) clean. A 90-day urine collection test was
completed on 27 June 89 in which a total of 2976 Ibs of urine was successfully
processed through an Representative Environmental Control System (RSECS) Urine
Separator with upstream liquid Oxone injection. Post test teardown demonstrated that
the internal hardware, which was primarily stainless steel, was kept free of urine
deposits with only the Oxone pretreat.
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Figure 1 Shuttle STS-65 Post Flight Inspection of Urine Separator
inside Surfaces Showing Excessive Urine Deposits After
Approximately 100 Kg (220 Ibs) of Urine Without Pretreat
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Figure 2 Shuttle STS-65 Post Flight Inspection of Urine Separator
Pitot Tube Showing the Pitot Inlet 90% Plugged with
Urine Deposits & Foreign Debris
The addition of Oxone to urine as the first step in the urine pretreat process does
provide partial pretreatment with the following results. As an "oxident", anti-microbial
control is achieved. The urine solution pH is lowered to about 4-5 which does fix urea
for room temperature conditions. The second step for full pretreatment of urine for the
downstream urine processing at elevated temperatures is the addition of H2SO 4 which
lowers the pH to approximately 2. For information the DuPont Product Specification
and Data Sheet for Oxone is included in Appendix C. The Material Safety Data Sheet
(MSDS) for Oxone is included in Appendix D.
DISCUSSION
The combined effort for the first phase of the urine pretreat injection system
investigation and test program was conducted for NASA/MSFC and ION. This first-
phase effort specifically addressed adding the Oxone ® portion only of the urine
pretreatment chemicals and included the following major tasks:
• Trade study for various Oxone injection concepts.
• Design and fabrication of prototype hardware of the selected concept.
• Prototype test verification.
Trade Study - The urine pretreatment trade, study began on 1 September 94 with the
"brainstorming" of various methods of introducing Oxone into a two-phase urine/air flow
stream in a microgravity environment. The trade study included dispensing of the
Oxone in different forms such as liquid, powder, paste and solid shapes. The trade
study included references and data from the early phase of the Commode/Urinal
System (C/US) development effort before the C/US portion of the task was put on hold.
At that point the baseline C/US schematic (SVSK117924) had defined the Oxone to be
injected as a liquid upstream of the urine separator. Refer to the schematic in Figure 3.
Some effort had been started to look at other injection concepts and these were
incorporated into the trade study.
The first trade study compared seventeen Oxone pretreatment concepts which were
composed of variations of Oxone-solution based systems, solid Oxone based systems,
systems which used powdered Oxone, and a system which used an Oxone paste. The
basis of the comparisons was a list of twenty "design & rating criteria." After review of
this initial trade study, NASA & HSSSI chose seven of the original seventeen concepts
for further, more detailed evaluation. This resulted in the second trade study. This
trade study suggested that a filter integrated solid Oxone-based system was the-most
viable given the rating criteria, which was the same used for the first trade study. Of the
seven concepts chosen for further evaluation, none was a liquid (Oxone solution)
injection-type system. However, during a subsequent phone conversation between
NASA, Boeing, and HSSSI, it was agreed that an automatic Oxone-solution injection
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Figure 3 Space Station Schematic (SVSK117924) Showing Last Baseline Version
of the C/US with the Liquid Oxone Injection Method.
system should be evaluated more carefully as compared to the solid Oxone system.
This was, in part, because an automatic Oxone-solution injection system had already
been presented at an earlier PDR as the baseline system. This resulted in the third
"trade study" being performed.
A review of the three trade studies shows that a passive method of urine pretreatment
which uses a 24-hour supply of solid Oxone integrated into the urinal filter is superior in
almost all of the twenty-one rating criteria to powder, paste, and solution systems. The
benefits of this type of system, hereafter referred to as the "tablets in-filter based
system," is given below with respect to each of the rating criteria.
Simplicity_ of Design - The tablets in-filter based system is by far the simplest
design with the exception of a manual Oxone pill method, which would require the
astronaut to insert an Oxone pill into the urinal before each micturation. Given a
C/US without any pretreatment system, only the filter bag need be modified to
accommodate the solid Oxone for this system to be incorporated. This would
involve lengthening the bag about 3-4 inches to accommodate the 24-hour supply of
solid Oxone rods (-1.1 in 3) and then cinching or seaming the bag above the Oxone
to insure it remains in the bag. (Note: a solid Oxone tablet is actually a combination
of powdered Oxone and a binder, probably polyethylene glycol, pressed into a
cylindrical form.) Many of the other systems evaluated required pumps, tanks,
sensors, injectors, electronics, and other mechanisms, in addition to modifications to
the existing urinal housing.
SimDlici_ of Use - The tablets in-filter system is the simplest of all the systems to
use because it doesn't require the astronaut to do anything new. The Oxone supply.
is automatically replenished every 24 hours because it is already a requirement that
the astronaut replace the filter every 24 hours.
Manufacturing Costs - Very low. Cost additions to a C/US with no pretreatment
system would include the manufacture of the solid Oxone rods and their integration
into the filters, both of which are expected to be fairly simple.
Handling Ease - The tablets in-filter based system will provide excellent handling
ease. There will be no bulky injectors or other mechanisms attached to the side of
the urinal housing to get in the way of the astronaut. Placement of the Oxone
loaded filter into the urinal assembly should be no problem as long as the fan in ON,
drawing air through the urinal hose.
f._ - The safety of the tablets in-filter based system should be as.good or better
than the other systems. According to the DuPont Technical Information brochure,
OXONE Monopersulfate has a low order to toxicity when taken internally. The lethal
dose for rats is 2250 mg/kg. Oxone is irritating to the eyes, skin nose, and throat
due to its acidity and oxidizing properties. DuPont observes an airborne exposure
limit to Oxone dust of 1 mg/m ", 8-hour time weighted average. There should be far
less opportunity for the environment to become contaminated with a solid system
than with a liquid or powder-based system, due to the inherent self-containment of
the solid system. The polyethylene glycol binder used in creating the Oxone solid
forms a wax-like material which precludes the likelihood of any Oxone dust forming
and getting into the air. In addition, the Oxone solid is contained within the tight
mesh of the filter, through which any Oxone particles are unlikely to pass. Two-fault
tolerant containment will be provided for both new and used filters. As is currently
done when handling a used urine filter on the Shuttle (for hygiene purposes), it
would be advisable to use rubber gloves when removing the used filters, as some
undissolved Oxone may remain in the filter.
Reliability_ - With no mechanisms, sensors, or electronics to fail, the tablets in-filter
based system should be the most reliable.
Ease of Maintenance - The tablets in-filter based system is essentially a disposable
system, therefore, it requires no maintenance.
Maintenance time - None.
Envelope of System - The tablets in-filter based system adds no envelope to a
C/US without a pretreatment system.
Weight of System - The tablets in-filter based system adds no weight to a C/US
without a pretreatment system.
Envelope of Logistics Supplies - The envelope of the filters would probably
double due to their increased length and Oxone load. The new and used filter
containers may also increase in size, depending upon the requirements of two-fault
tolerant containment. Still, the tablets in-filter based system is expected to have the
smallest logistics supply envelope of all the systems. 1 Additional weight will
include the weight of the solid Oxone itself (about 47 gms/day), a tiny amount of
weight from increased filtration media, and any additional weight caused by the
need for two-fault tolerant containment for the new and used filters.
Ease of Retrofit into Orbiter (Adaptability_ for Use with Citric Acid! - The use of
citric acid as a pretreatment is the current baseline for the Shuttle. The tablet in-
filter based system should be as adaptable for use with citric acid as any of the
systems evaluated. Citric acid is easily formed into a dissolvable solid and is
expected to require a smaller volume per dose than Oxone. (See the "Air Flow
Impedance" criterion.) Also, this system requires no additions or modification to the
existing Orbiter WCS and EDO WCS hardware, except for the modest filter
redesign. (Note: EDO = Extended Duration Orbiter)
I Except for the manual Oxone pill system.
• Usability_ in ISSA Commode/Urinal - Expected to be the best system, due to its
simplicity.
Material ComPatibility - None of the Oxone systems are expected to pose a
material incompatibility problem with the rest of the C/US. However, unlike some of
the other systems evaluated, the tablets in-_lter based system cannot pose any
materials incompatibility problems to itself simply because it adds no new hardware
or materials to the C/US.
Development Risk - The tablets in-filter based system has the lowest development
risk of all the other systems. 1 The formation of the Oxone into a solid form has
already been demonstrated. The formulation and geometry of a solid containing 42
grams of Oxone must be developed such that it dissolves fairly uniformly over a 24-
hour period of average, intermittent micturations.
• Development Cost - Similarly, the tablets in-filter based system should have the
lowest development cost associated with it..1
Air Flow Impedance - Although for this category the tablets in-filter based system
ranks substantially higher than most of the powder or granular based "tea-bag"
systems, this is the one category where it ranks lower than the paste or liquid
systems. However, both analysis and actual testing has shown that the additional
pressure drop caused by a rod loaded filter compared to an unloaded filter is only
about .25 in. H20, or less than a 1 CFM drop in flow given an unloaded flow rate of
10 CFM.
• Power Consumption - The tablets in-filter based system uses no power.
The trade study was completed and presented at a formal review on 24-25 October
1994. The selected concept for further investigation and test was the solid
Oxone/binder tablets held in a permeable membrane casing. A copy of the trade study
as presented is included in Appendix A.
The most significant improvement in the Oxone tablet during the trade study was the
identification of using Polyethylene Glycol (PEG) as the binder over the previously
selected (plasdone) binder. Based upon some preliminary benchtop tests during the
trade study PEG appeared to demonstrate better controllability over the dissolution rate
with a liquid flowing over the tablet. Moreover as the tablet dissolved it reduced in size
more uniformly from the outer surface and did not erode into pieces like the Oxone with
the plasdone binder. This feature along with the other discriminators of.the trade-study
provided the backup necessary for the decision to use the solid Oxone tablet with the
PEG binder.
1 Except for the manual Oxone pill system.
10
Design and Fabrication - The design phase of the program started with the concept
sketches of the selected approach and expanded the drawing definition to the detail
necessary to fabricate the required hardware for the final test phase. In the design
phase several areas of concentrated effort were completed. These included the
following: (1) Definition of new configuration prefilter housing, (2) Layout of the pretreat
prefilter assembly to contain the tablets, and (3) tablet dissolution rate. The following is
a list of design requirements and assumptions used for the design and test of the
selected concept for the Oxone pretreat method:
• Pretreat system must introduce Oxone upstream of the separator.
• System will be used in conjunction with a sulfuric acid injection system
downstream of the urine separator.
• 1.5 grams of Oxone required per average (300 ml) micturation.
• Space Station Urine Process Rate is 3.44 Ibs urine/day/crew member. (1.56
liters/day).
• Flush Water is 1.09 Ib/day/crew member (test at 80 ml/flush).
• Twenty-eight micturations per 24 hour period for a four member crew.
• 270 day total logistics storage timeline.
Urine Prefilter Housing Design - The present design of the urine prefilter housing for
the EDO WCS is basically the same as the non-EDO version of the WCS. It has a
nominal 7/8" internal diameter to match the urine collection hose and is hinged to allow
insertion of a urine prefilter that is changed daily or twice a day depending on the use
rate. (Reference Figure 4). The new solid Oxone tablets inserted into the hose causes
an increased airflow restriction and a higher flow AP. A corresponding loss in air
entrainment airflow would reduce the effective fluid (urine) containment. To offset the
effect of reduced airflow area in the hose, it was decided to enlarge the I.D. of the
existing housing to 1 inch. The increase in I.D. necessitated an inlet housing redesign
which, simplified the original multi-piece hinged configuration (reference Figures 5 & 6)
to a single detail part. The features of this redesign are several:
1) The hinge joint with the finger latch for insertion of the prefilter seal is
eliminated.
2) The prefilter seal now fits into the funnel end of the housing and doubles as a
non-metallic seal between the housing and funnel.
11
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Figure 4 Existing Shuttle WCS Configuration of the Various Hardware
Associated with Urine Collection at the Funnel and Prefilter Area
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Figure 5 Comparison Between the Existing Hinge-Type Inlet
Prefilter Hous:,ng and the Single Piece UPIS Redesign
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Figure 6 Exploded and Assembiy Views of the Prefilter and Funnel
Along with the Redesigned Prefilter Housing (Reworked
Old Configuration C/US Prefilter Used for Demonstration)
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3) The original metallic seat with the backup wave spring has been eliminated
which minimizes trapped residual urine and its associated cleaning problems.
4) The O.D. of the prefilter housing remained at the same size such that the
mating yoke that holds the housing would not be affected.
5) Finally, with the large housing I.D. a prefilter with a greater surface area and a
corresponding lower z_P can be utilized.
A detail drawing of the new prefilter housing (SVSK116871) is shown in Appendix B. In
addition to a simpler design and the stated functional advantages, the new prefilter
housing only weighs 127 grams (0.057 Ibs) which is over a 40% weight savings over
the old design housing of 215 grams (0.097 Ibs.).
Urine Pretreat Prefilter - The design effort also included drawing definition of the
prefilter/Oxone assembly. A cross section view is shown in Figure 7 and the complete
drawing is enclosed in Appendix B. Once the trade study decision was made to use the
solid tablet in a casing concept it was a matter of design definition to consider the
various requirements for proper operation, ease of manufacturing, selection of materials
and sizing. The size of the tablets; ie., length and diameter, was based on several
issues. The tablet assembly had to fit into an existing 7/8" I.D. urine hose without
significantly decreasing the flow cross sectional area and restricting airflow. The
existing laboratory pill press was 0.5 inches in diameter. A wood mockup dummy was
fabricated of the prefilter/Oxone assembly using 1/2" dowels as tablets. The mockup
was hung in the benchtop airflow rig with a 7/8" I.D. Lexon tube with 10 CFM of airflow
which demonstrated that the slight increase in AP was tolerable. This test was
conducted prior to availability of the new designed larger 1.00" I.D. prefilter housing
which slightly decrease the z_P. Recognizing that the tablets would increase the AP, the
goal was to offset this effect with the slightly larger I.D. urine inlet housing. This allows
a larger urine inlet prefilter with more filter surface area and less AP.
Once the diameter of the Oxone tablet was established, the overall length of the
prefilter/Oxone assembly was determined. The primary factors that dictated the length
were the total quantity of Oxone required for one batch and the convenience of
handling. For ease of handling it was obvious that the shorter the assembly the better
and over 12" length would not be recommended. The total Oxone required per change-
out period (or batch) was dictated per the design requirements of a minimum of 5 grams
of Oxone per liter of collected urine. For purposes of discussion in this report, one
batch is defined as the total quantity of liquid collected to dissolve one prefilter/Oxone
assembly. The total quantity of liquid collected relates to the use rate (number of
astronauts on board), the change-out frequency (once or twice a day), and the quantity
of flush water.
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Figure 7 Layout of the Urine Pretreat/Prefilter Assembly that Contains Several
Oxone Tablets in a Casing Attached to a "Wind Sock" Type Debris Prefilter
Based on the above variables, the total quantity of Oxone required per prefilter/Oxone
assembly could range considerably. This is considered acceptable since the concept of
individual Oxone tablets assembled into a casing allows a variable quantity of tablets to
be used (i.e., 4 to 8 per assembly depending on the mission or use rate). During the
test program each tablet contained about 6 grams of Oxone and binder. A total of 8
tablets were contained in each urine pretreat/prefilter assembly (see.Figures 8 & 9).
Therefore, each test assembly contained approximately 48 grams of Oxone and binder.
Subtracting out the binder this would leave 46.3 grams of Oxone for pretreating 9.26
liters (20.6 Ibs) of urine maximum at 5 grams o_f Oxone per liter of urine.
Oxone Table Dissolution Rate - Another key factor in definition of this concept for
urine pretreat was establishing an acceptable and controllable dissolution rate of the
Oxone tablet in a two-phase stream of urine and air. The starting point for this
investigation was the previous effort under the baseline Space Station Commode/Urinal
System (C/US) program which defined plasdone as a prime candidate binder. A binder
is necessary to hold together the compressed Oxone powder in a tablet form and
provide a slower and controlled dissolution rate for releasing the Oxone into the
collected urine. The plasdone did slow down the dissolution rate of the tablet.
However, it still allowed large pieces of the tablet to erode (or break) off. This condition
was unpredictable and the smaller chunks caused a variation in the dissolution rate.
Polyethylene Glycol (PEG) was selected as an alternative binder to correct this
condition. Various molecular weights, PEG to Oxone ratios, and mixing processes
were investigated to provide an Oxone tablet that could be properly pressed and have
the acceptable dissolution rate. After mixing and processing the Oxone powder and the
PEG, approximately 6 grams of the material can be loaded into a 0.5 inch diameter
cavity die and would be pressed into a tablet form. A Carver model "C" manual
hydraulic press was used to provide a maximum load of 20,000 psi. The original Oxone
powder is reduced in volume by a compaction ratio of 1.8:1. The final compressed size
of a 6 gram tablet is 1.27 cm (0.5 inches) in diameter by 2.03 cm (0.8 inches) long.
A benchtop test rig was built to assist in obtaining a more controllable measure of
dissolution rates while exposing a tablet or prefilter pretreat assembly of tablets to a
more realistic or standard set of inlet conditions. The rig schematic is shown in Figure
10 and a photograph is shown in Figure 11. To obtain a baseline dissolution rate of the
Oxone tablets during initial testing it was decided to use only water for which quantity,
flowrate, and temperature could be easily controlled by this rig. An airflow rate of 10
cfm was provided to duplicate the airflow rate of the Space Station urinal. A clear
length of 7/8" I.D. Lexon tubing was installed to simulate the urine collection hose and
to visually inspect the liquid flow over the tablet (or prefilter assy). In addition, the-tube
was positioned vertically to minimize the effects of gravity during two-phase flow.
(Refer to Figure 12).
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Figure 8 Photo of a Typical Urine Pretreat Prefilter with Eight Oxone
Tablets and an Overall Length of Approximately 11.50 inches
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Figure 9 Photo of Urine Pretreat Prefilter Showing Flexibility
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Figure 11 Photo of the Dissolution Rate Test Rig
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Figure 12 Closeup View Showing a Typical Urine Pretreat
Prefilter Hanging in a Clear 7/8" I.D. Tube to
Simulate the Urine Collection Hose
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A series of tests were conducted using this rig which included the following: single
tablet, multiple tablet, and &P tests.
Single Tablet Tests - Test conditions for the single tablet "quick" tests were as follows:
Perimeter Tablet #1 Tablet #2
Initial Tablet Weight (g)
H20 Flow Time (sec)
H20 Flow Rate (ml/sec)
Air Flow Time (min)
Air Flow rate (CFM)
Flush H20 Used
5.13 5.59
20 20
25 20
3 3
10 10
None None
Figure 13 shows the tablet weight versus number of cycles plot of Tablet #1 and Tablet
#2. The shape and slope of the curves are characteristic for tablet dissolution rate in a
cyclic two-phase flow stream. The curve, for discussion purposes, is divided into three
areas (or rates).
The first portion of the curve represents the initial wetting of the tablet with an
associated smaller weight loss. The middle portion of the curve has a greater slope
with a larger weight change between each cycle. The last portion of the curve has a
lesser slope as the weight change starts to fall off. It was observed during this portion
of the curve that the tablet size had been reduced significantly along with the surface
area. Therefore, the cyclic weight reduction was less. To obtain this curve the tablet
had to be removed after each cycle of input H20 flOW. During this test the input H20
was also pretreated to approximate body temperature. The actual temperature
recorded in the data sheets shown in Appendix E was the inlet peak temperature during
the 20 sec flow time. The peak inlet temperature ranged from 98.2 to 104.4°F. During
testing of Tablet #2 a pH test was conducted on the downstream flow during each flow
cycle to obtain an instantaneous pH reading. To obtain this reading a pH indicator strip
was inserted into the flow stream. As expected the pH was lower during the earlier
cycles and as the tablet was reduced in size the pH was higher. The pH initially ranged
about 3 1/2 to 4 and finally rose to 4 1/2 to 5. The reasons for conducting these single
tablet tests were mostly exploratory and to check out the bench setup. However, the
results indicated that the concept was working sufficiently to proceed to a
prefilter/multiple Oxone tablet assembly.
Multiple Oxone Tablet Assembly Tests At this point in the test program the
fabrication of Oxone tablets and prefilter assembly had progressed enough to initiate
testing at the multiple tablet level of assembly. Six (6) tablets were processed and
pressed with 10% PEG. Each tablet weighed approximately 5 grams and the total
tablet weight for the assembly was 31.66 grams (see data sheet in Appendix E). The
23
Figure 13 Test Results for the Dissolution Rateof Two (2)
Individual Oxone Tablets
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test was conducted by inserting the prefilter assembly in the simulated urine collection
hose as shown in Figure 12. Inlet test conditions were set up as follows:
H20 Flow Time (sec)
H20 Flow Rate (ml/sec)
Air Flow Time (min)
Air Flow Rate (CFM)
Cycle Duration (Tin)
Flush H20 Used
20
20
3
10
5
None
Figure 14 shows a plot of total tablet weight versus cycles (or uses). Again the curve
shows the characteristic shape of the initial wetting, the early steep slope, and the final
portion where the dissolved quantity of tablet decreases per cycle. The test was
stopped after 20 cycles were completed and the total residual undissolved weight of the
tablets was 0.87 grams. Subtracting this from the initial weight and also subtracting
10% PEG resulted in 27.91 grams of Oxone dissolved. Over the 20 cycles a total
throughput of 9.33 liters of H20 was collected. The ratio of grams of Oxone to liters of
water was 2.99, which was below the goal of 5 grams/liter. The low ratio of 2.99
grams/liter was considered to be within an acceptable range at this point in testing
since heated water was used as a test fluid. A more realistic dissolution rate was
expected with the use of fresh urine. The pH of the 9.33 liters of water in the collection
reservoir was 3. The initial flowstream pH reading was 2 1/2 and after 20 cycles was at
4 to 4 112. It should be noted that the pH with water is expected to be slightly lower
since urine will buffer the acidity of the Oxone.
Pressure Drop Tests - As previously mentioned there was a concern that the Oxone
tablets hanging in the urine collection hose would cause a slight reduction in airflow
because of the additional AP. The tare AP of a funnel and 7/8" ID Lexon tube was
recorded at 0.8 inches of H20 at 10 CFM. Adding the six (6) tablet urine pretreat
prefilter increased the AP to 1.7 inches of H20. Therefore, the actual differential
pressure for the prefilter assembly is 0.9" of H20 which is still less than the specifcation
limit of 1.0" of H20 for the prefilter by itself. The new prefilter housing internal diameter
was enlarged to a 1.0 inch diameter and with a matching larger prefilter surface area
would offset some of the increased AP of the Oxone tablets. A new larger surface area
prefilter was not available for testing at this time.
Prototype Test Verification - This portion of the urine pretreat injection test program
includes several types of tests to verify the concept and prototype hardware. The tests
to be discussed are:
• day long term urine collection
• Oxone concentration evaluation in urine
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Figure 14 Test Results for the Dissolution Rate of a Six (6)
Tablet Urine Pretreat Prefilter
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• microbial air sampling
• Oxone tablet storage stabilization
30-Day Long-Term Urine Collection Test - This test was the most significant test to
verify the acceptability of this concept because it was conducted with fresh collected
urine using actual concept pretreat hardware that was previously installed on the
Shuttle EDO DTO urinal over a sufficient period of time. The test plan for the urine
collection test is included in Appendix F. The portable test rig was fabricated using the
Shuttle EDO DTO Urine Fan/Separator with clear Lexon housings. This Urine
Fan/Separator, Hamilton Standard P/N SV 805378-1, was authorized to be used for this
test program by Rockwell/NASA JSC and is the same hardware baselined for the
Space Station Commode/Urinal System. Figure 2 of the test plan in Appendix F shows
a schematic of the portable urine collection test rig and Figures 15 thru 17 show the rig
prior to testing. For ease of operation by male volunteers the rig was modified to add a
automatic "on"/"off" user lid, see Figures 18 & 19. Also, the Fan/Separator, itself, was
lowered to allow the clear Lexon tube to be as vertical as possible for convenient use in
a one-gravity ("terrestrial") mode.
On 12 February 95 a pretest baseline test was performed on the portable urine
collection test rig to establish the operational characteristics of the Fan/Separator prior
to exposure to long term urine and pretreat testing. This test was conducted using
water as a test fluid. Test results are shown in Table A. Also, as part of the baseline
test an eight (8) tablet urine pretreat/prefilter was subjected to a dissolution rate test
using water in the benchtop dissolution rate test rig. For this test and the subsequent
tests each urine pretreat/prefilter was assigned a serial number (i.e., S/N UPIS-XXXX)
which would be associated with a specific batch of collected test media (i.e., BATCH #
UPIS-XXXX). A plot of total tablet weight versus use cycles is shown in Figure 20.
The long-term urine collection test with pretreat was started on 14 February 95. Prior
to the workday the portable urine collection test rig was positioned in a heavily traveled
men's bathroom for "real time" urine collection and pretreatment by interested
volunteers. A fresh urine pretreat/prefilter assembly (SIN UPIS-A001) was installed in
the prefilter housing to collect the first batch. A stereo lithography (SLA) translucent
prefilter housing identical to the titanium housing was used for viewing purposes. After
about 4 1/2 hours 4 of the 7 tablets were totally dissolved and a data st 'et was filled
out for the first batch of collected and pretreated urine. The first of 40 uata sheets is
presented in Figure 21 for batch #UPIS-A001. After draining the collection tank (one
batch) a new urine pretreat/prefilter was inserted for the next batch collection and data
point. To obtain consistent data it was necessary to eliminate as many of the
controllable test variables as possible. The following conditions were considered
controllable variables:
• Batch Start Time - After the first several batches it was determined that the
use rate (i.e., number of walk-in donors) would only support one batch a day.
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Figure 16 Side View of the Portable Urine Collection Test Rig
Showing the 120 VDC Power Supply, Control Box,
Flush H20 Pump_ and Clear Odor/Bacteria Filter Housing
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FFigure 17 Side View of the Portable Urine Collection Test Rig
Showing the 35 Liter Pretreated Urine Reservoir
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Figure 18 User Interface View of the Portable Urine Collection Test
Rig Showing the Lowered Position of the Urine Fan/Separator
and the Manual "Lift On"/"Close Off" User Control
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Figure 19 View Showing a Partially Dissolved Urine Pretreat
Prefiiter installed and the Clear Separator Housing
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Table A Portable Urine Collection Test Rig
Pre and Post Baseline Test Results
Condition/Parameter
Date of Test
Pre Filter Used
Start/Start Cycle Readout (cycles)
Test Rig Counter (cycles)
Separator Running Time (Hr)
Voltage Supply (VDC)
Total Current Fan/Sep (Amps)
Fan Current Steady State (Amps)
Fan Current Max Start Up (Amps)
Sep Current Steady State (Amps)
Sep Current Max Start Up (Amps)
Tank Pressure (psi)
Sep Outlet Pressure (psi)
Fan/Sep Post Use Run Time
Flush Time (sec)
Flush H20 Qty (ml)
Post Test Flush of System
Pretest
12 Feb 95
Mockup Pretreat
Filter Assy
91
021678
2.3
120 VDC
0.85-0.90
0.60
0.8
0.42
1.2
8.0
10.0
1 min, 8 sec
29 sec
80 ml
N/A
Post Test
2 May 95
Mockup Pretreat
Filter Assy
1467
023054
54.5
120 VDC
0.88-0.90
0.55
0.8
0.4
1.2
8.0
9.0
1 min, 8 sec
29 sec
79 ml
2 liters
!
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Figure 20 Dissolution Rate Curve for Pretest Baseline
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Figure 21 Typical Data Sheet Filled Out for Collection of One
Batch of Pretreated Urine
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Starting a collection batch at the beginning of a work day provided a relatively
consistent donation population and the tablets would be dissolved around
noon to mid-afternoon. This. was also convenient for setting up before the
day shift started and then taking data in the afternoon during the slow use
time. This sequence also eliminated the variable that was noted for batch
#UPIS-A002, which was started in the afternoon. After the day shift when the
test was secured, there were still over 3 grams of Oxone left in the prefilter
assy. For batch #UPIS-A004 the same mid-day collection start time condition
occurred and it was decided to leave the undissolved tablet assembly in the
test rig overnight (-16 hours without use) causing another variable.
Residual Undissolved Oxone - The most opportune time in a urine batch
collection process would be to stop collection is the point when the last
tablet(s) dissolved into the flow stream. This was not totally practical since
this was a visual observation and somewhat objective as to when the last
granule of Oxone dissolved. If the tablet assembly was removed too soon
the calculated ratio would be too high. If the tablet assembly was left in the
rig excessively long after completely dissolving the dissolution rate calculation
would be inaccurate and also allow some untreated urine thru the separator.
Therefore, towards the end of the batch cycle as the tablets dissolved the rig
would be checked routinely to visually determine the best time to take data
points.
The urine collection test was conducted over an eleven (11) week time period for
a total of 40 batches collected with the last batch collected on 28 April 95. Table
B is a summary of the data collected from the daily data sheets. The following
are explanations of each column of the daily summary data sheet:
• Batch I.D. number - This is the identification of the batch of urine collected
from UPIS-A001 thru UPIS-A040 for a total of 40 batches.
Use Cycles per Batch - This is a count of the total number of times that the
rig was cycled. This is assuming that nobody played with the lid causing
extra cycles. Conversely, fewer cycles would have been recorded if the unit
was used sequentially by two people without shutting the lid. It is believed
that these readings are reasonably accurate. Therefore, the data was used
to obtain the quantity of flush water processed. Cycles ranged from a low of
16 to a maximum of 42 with an average of 32. A total of 1276 use cycles was
accumulated during the test.
,J
QtY Liauid per Batch - This was the total quantity of liquid collected in the
reservoir of the portable collection rig per batch. This included 80 ml of flush
H20 that was collected automatically after each use. An average of 11.0g
liters of liquid was collected per batch.
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Table B Summary of Initial Data From UPIS Data Sheets
BATCH IO
NO
USE CYCLES QTY LIQUID WEIGHT OF PRETREAT TO RESIDUAl BATCH AVERAGE SEPARATOR AVERAGE
PER BATCH PER BATCH PRETREAT LIQUID RATIO PRETREAT ACIDITY OF VOID LESS RUNNING TIME RUNNING TIM1
(NO) (mL) USED (g) (g/Liters) (9) BATCH (pH) OXIOATION FLUSHVALUE (%) (hi) (MIN/CYCLEI(mL}
UPIS-AOO1 24 7170
UPIS-AO02 16 5440
UPIS-A003 25 8800
UPIS-A004 24 6710
UPIS-AC05 25 7440
UPIS-A006 34 11340
UPtS-A007 27 9800
UPISA-006 27 8440
UPIS-A009 32 12070
UPIS-A010 : 30 i2610
UPIS-A011 37 15150
UPIS-A012 31 11340
UPIS-A013 32 11160
UPIS-A014 31 10800
UPIS-A015 35 10030
UPfS-A016 "29 11160
UPIS-A017 31 11880
UPIS.A018 34 12880
UPIS-A019 34 12520
UPIS-A020 31 10020
UP,S-A021 33 11700
UPIS-A022 37 12340
UPIS-A023 30 10400
UPIS-A024 42 12160
UPIS.A025 33 8980
UPIS-A026 35 • 12880
UPIS-A027 33 12880
UPIS-A028 27 9620
UPIS-A029 36 11520
UPIS-A030 41 13790
UPlS-A031 31 11520
UPIS-A032 37 12340
UPIS-A033 34 11790
UPIS-A034 34 12340
U=IS-A035 36 12700
L _tS-A036 29 11100
UPIS-A037 33 11000
UP15-A036 33 12800
UPIS-A039 36 13610
UPIS-A040 37 11800
TOTALS 1276 444030
Averages 32 11090
44.09 6 15 <0 05 3 1/2-4 219 0.8 2 00
38.24 703 3 07 4 00260% 260 0 6 2 25
46.02 5.23 0,63 4 1/2 0.0200% 272 09 2 16
47.94 7 14 0,00 4 00400% 200 09 2 28
4646 625 - 0.20 4 00320% 218 0 8 1 92
47 42 416 0.00 4 1/2 0.0130% 254 1 3 229
48 11 4.91 ~ 0.50 4 00320% 283 0.9 2 00
066 4 1/-,2 00095% 232 09 2_00
<O10 4 1/-,2 0.0036% 297 1 2 2.25
41 90 4.97
4588 3.80
45 61 3 62 <0 10 5 0.0097% 340 1 2 2 40
46.95 310 -0.20 5 0.0059% 329 1 4 2 27
47,45 418 <010 4 1/2 0.0170% 286 1 1 213
4808 4.31 <O10 4 1/2 0.0160% 269 1 1 2 06
47.07 4.36 "0.20 4 I/2 0.0214% 268 1 1 213
47=75 4.76 0.39 4 1/2 0.0085% 206 1.2 2 06
45.02 4.03 0.00 4 1/2 00250% 304 I 0 207
47.85 4.03 <005 5 0.0130% 303 1.2 232
47.97 3.72 <0.05 4 1/2 0.0062% 299 1 3 2.29
46.0_ 3.84 <005 4 1/2 0.0130% 288 13 229
4789 4.78 0.27 4 1/2 0.0150% 243 I 1 2 13
48.11 4 11 <0.10 4 1/2 0.0180% 275 1.1 200
48.09 3.90 0.13 5 00099% 253 0.4 0 65
48,30 460 <0.05 4 1/2 0.0120% 268 1.0 200
48.18 3.96 0.00 5 0.0044% 209 1 6 2,29
4773 5.31 0.55 4 1/2 0.0057% 192 11 200
48.12 3.74 <0.08 4 1/2 0.0067% 286 1.2 205
4824 3.75 0,00 4 1/2 0.0053% 310 1 1 2 00
47.97 4.99 0,25 0.0320% 276 0,9 2 00
47,35 4,11 1,02 _ 240 1,2 200
47.66 3.46 0.00 _ 256 1.5 223
48.04 4.17 <0.30 _ 292 1 3 2.52
48.16 3.90 0.21
48.20 4.09 -0.10
4802 3.89 --0.25
48.04 3.78 >0.10
48.19 4.34 0.00
48.22 4.38 0.00
47.74 3.73 0.38
4815 3.54
48.08 4.08
1886.38
-0,10
-015
416
4
41/"2
5
41/-.2
41/'2
41/2
5
41/2
4 1/2
4
8
5
41/2
253 1.3
267 1.3
283 1.2
273 1,2
2.11
2.29
2.12
2,00
303 1.0 2,07
253 1.1 2,00
308 1 1 2.00
298 1.7 2 83
239 1.3 2 11
_ 4490
47,14 4.54 0.22 4.54 0.0156% 267 1.t 210
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Weight of Pretreat Used - This is the total weight of the tablets used in
grams which includes the binder. During the fabrication of the urine
pretreatJprefilter each assembly was serialized and the total weight of the
Oxone tablets including binder was recorded. The average total weight of
eight (8) tablets in a prefilter assembly was 47.14 grams.
Residual Pretreat - This was the total weight in grams of the undissolved
tablets. As previously discussed an attempt was made to stop urine
collection for each batch as the tablets were just about totally dissolved or
shortly thereafter. When the used prefilter assembly was removed, it was
visually inspected and the number of undissolved tablets would be recorded
on the data sheet. Also, all of the undissolved chips would be cut out of the
prefilter casing, weighed, and recorded.
A_idit'y of the Batch - This is the pH reading taken on each batch using a
litmus strip indicator. The procedure used was to drain about 1/2 of the rig
collection reservoir. At this point the pH strip was held in the flow stream to
get a reading. A second strip was used to back up the reading. The range of
pH readings was usually between 4 to 5 with an average of 4 1/2 over 40
batches.
Batch Oxidation Value This is the percent of active oxygen in the
pretreated collected urine. After each batch was collected, a 180 ml sample.
was drawn from the rig reservoir and analyzed. The method used was the
standard iodometric titration recommended by DuPont in the Oxone data
sheet. The Oxone data sheet is included in Appendix C.
Average Void Less Flush This is a calculated value of the average
quantity of void in millimeters per each batch. This void volume was obtained
by subtracting the 80 ml of flush water per cycle from the total liquid collected
and dividing by the number of cycles per batch. The average void volume for
the 40 batches was 267 ml.
SeDarator Running Time - This is the total of time in hours for the Urine
Fan/Separator as recorded by an elapsed time indicator. The total separator
operating time for the complete test was about 45 hours which included at
least 1276 on/off cycles.
Average Running Time - This is a calculated time in minutes that the
Fan/Separator would be running for each use (or void). The ayerage on time
is 2.1 minutes which includes the post use time delay shutdown period of 45
sec.
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Table C includes a continuation of the data recorded and calculated from the daily data
sheets. The following are explanations of each column of the calculated data sheet:
• Batch I.D. No. - same as Table B,
• Weight of pretreat and binder - same as Table B.
• Percentage of binder. This is the nominal percentage by weight used to
process the individual Oxone tablets.
Weight of Dretreat only - This is the total weight of the tablets in grams with
the appropriate percentage of binder subtracted out. The average weight of
Oxone available per prefilter/pretreat assembly was 45.55 grams.
• Qty of Liauid per Batch - Same as Table B.
Qty of Flush Per Batch - This is the total calculated volume in millimeters of
flush water used in each batch. The volume was obtained by multiplying the
void cycles by 80 ml per void.
Qty_ of Urine Der Batch - This is the total calculated volume in milliliters of
urine per batch less the flush H20. The average volume of urine collected
per batch was 8.55 liters.
Ratio of Oxone to Urine - This is the calculated ratio in grams of Oxone per
liter of urine. The goals of the test program was to demonstrate a proper
pretreat ratio of at least 5. grams/liter.
Total Qty_ of Urine Collected - This is a cumulative record of the urine
collected for the 40 batches. The total volume of urine pretreated and
collected was 342 liters.
Figure 22 is a plot of the Oxone to urine ratio for the total of 40 batches (or "data
points"). The primary goal was to have the batch concentration ratio of Oxone to
urine be just slightly higher than 5.0 grams/liter. It was assumed that there would
be several uncontrolled variables that would cause the ratio to vary slightly from
batch to batch. It was also assumed that the dissolution rate with fresh urine
would have to be modified slightly to "zero in" on the 5.0 grams/liter goal. As
demonstrated by the plot, the first few data points grounded around 8 grams/liter.
Since the trend was on the high side the dissolution rate had to be slowed down
slightly by changing the percentage of PEG from approximately 2.5% to 3.5%.
This was a best estimate type of change but the results indicated that the trend
in Oxone to urine ratio was reduced with the higher PEG percentages. Again
several batches were observed and the average ratio did fall to an acceptable
level. No further changes in the Oxone tablet chemical composition and
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Table C Summary of UPIS Calculated Data for Urine
Pretreat Test
BATCH I D NO
UPIS-A001
UPIS-A002
UP1S-A003
UPIS-A004
UPIS-AO05
UPIS-A006
UPIS-A007
UPIS-A008
UPIS-A009
UPIS,A010
WEIGHT OF
PRETREAT &
BINDER
(g)
4409
3824
4602
47.94
4646
4742
48 11
41 90
45.88
45 61
PERCENTAGE
OF BINDER (%)
2.5%
2.5%
WEIGHT OF
PRETREAT
ONLY (g)
42.99
37.28
IOT_ OF LIQUID
PER BATCH
(mL)
7170
5440
QTY OF FLUSH
PER BATCH
(mL)
1920
1280
2.5% 44,87 8800 2000
2.5% 46.74 6710 1920
3.5% 44.83 7440 2000
45.76
46.43
40.43
4427
3.5%
3.5%
3.5%
11340
9800
8440
12070
12610
3.5%
3.5% 4401
272O
2160
2160
2560
2400
QTY OF URINE
PER BATCH (mL)
RATIO OF
OXONE TO
URINE (g/hter)
TOTAL QTY
OF URINE
COLLECTED
(L.ters)
5250 8 19 525
4160 896 941
6800 660 16.21
9.76 21004790
5440
8620
764O
6280
9510
10210
UPIS.A011 46 95 35% 45.31 15150 2960 12190
UPIS-A012 47 45 3.5% 45 79 11340 2480 8860
OPIS.A013 48 08 3.5% 46.40 11160 2560 8600
UPIS-A014 4707 3.5% 45,42 10800 2480
UP{S-A015 47 75 3.5% 4608 10030 2800
UPIS-A016 45 02 3.5% 43.44 11160 2320
11880
12880
4785
4797
48 09
UPIS-A017 4618
4629
46.41
46.21
2480
2720
2720
2480
3.5%
35%
3.5%
3.5%
UPIS-A018
UPlS-A019
UPIS-A020 47 89
8.24 2644
5.31 3506
6.08
6.44
466
4.31
12520
42.70
48.98
58.49
68.70
3.72 80.89
517 89 75
5 40 9835
8320 5.46 10667.
7230 6 37 11390
8840 491 12274
491 132.14
1002O
9400
10160
98O0
7540
4 56 14230
474 152,10
613 15964
5 12 168.70UPIS-A021 48 11 3.5% 4643 11700 2640 9060
UPIS-A022 48 09 3.5% 46,41 12340 2960 9380 4 95 178.08
UPIS-A023 4830 3.5% 46,61 10400 2400 8000 5.83 186.08
12160
8980
12880
12880
9620
11520
13790
11520
12340
11790
3.5%
3.5%
3.5%
3.5%
3.5%
3,5%
48 18
47 73
48 12
48.24
4797
47 35
3360
2640
2800
264O
2160
2880
3280
2480
2960
'2720
47.66
UPIS-A024
UPIS-A025
UPIS-A026
UPIS-A027
UPIS-A028
4649
4606
4644
46.55
46.29
45.69
45,99
46.36
46.47
46.51
UPIS-A029
UPIS-A030
UPIS-A031
UPlS-A032
UPIS-A033
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13610
11800
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Av 9 of 1-5
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6340
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9380
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528 194.88
7 26 201 22
4.61 211 30
4.55 221.54
6.21
5.29
22900
23764
4.38 24815
5.13 257.19
4.95 266.57
5.13 275.64
47.74
48 15
2.7%
48 08
4716
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46.46
46.40
9620 4.82 285.26
9820 4 72 29508
8780 5.30 303,86
8360 5.57 312.22
10160
10730
8840
453
4.33
525
5.58
8 35
45,55
43.3444 55 7112
2552
1824
8549
5288
322.38
333.11
341 95
8.5
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processing were made. The final average for batches UPIS-A006 thru UPIS-
A040 was 5.2 grams of Oxone per liter of collected urine.
On 28 April 1995 the last batch was collected for a total quantity of urine
processed at 341.95 liters (754 Ibs). After the last batch was collected a post
test baseline check was conducted on the fan/separator. Test results are shown
in Table A and compared with the pretest results indicate that there was no
performance degradation in the operation of the separator.
After completion of all testing the portable urine collection test rig was partially
disassembled for post test evaluation of the Urine Fan/Separator and plumbing.
A teardown of the Fan/Separator was conducted to visually examine the areas
that were exposed to the collected urine. Figures 23 and 24 show some of the
detail subassemblies and internal parts of the separator with no evidence of
urine deposits. The same was true for the downstream dual in-line check valve
teardown'shown in Figures 25 and 26. Figure 27 shows other miscellaneous
parts that were exposed to the urine, i.e., Lexon inlet tube, 90 ° stainless steel
inlet elbow, 3/8" outlet tygon tubing, and outlet quick disconnects with tee. Refer
to Figure 1 and 2 for a comparison of urine fan/separator details which were not
pretreated with Oxone.. These details were exposed to only one flight for
approximately 100 Kg (220 Ibs) or urine.
A closer look at the outer o-seal area of the rotating Titanium drum showed some
evidence of foreign material. These small particles were driven into the inboard
side of the o-seal area by the centrifugal force of the rotating drum. Figures 28,
29, and 30 are magnified views of the debris which is considered to be small
enough in size to have entered through the pores of the inlet prefilter. The small
fibrous white material (or lint) was drawn into the separator by air entrainment of
which most could be captured in the prefilter. The small red material (or chips)
are from the reworked prefllter seal area which is a red silicone elastomer. It is
not expected that these chips would be present on a flight quality
pretreat/prefilter assembly. Refer to Figure 6, which shows a typical test prefilter
that was cut down for use in the urine collection test.
Oxone Concentration Evaluation in Urine - During urine pretreat test program
it was considered necessary to determine the minimum Oxone concentration
level that would provide control of microbial growth in urine. A separate quantity
of urine was collected in a container without pretreat and provided to the
Microbiology Lab for evaluation. Data indicated that for Oxone concentrations as
low as 4.0 grams/liter provide excellent microbial growth control arid; levelsdown
to 3.0 gram/liter still provide partial control in collected urine at room
temperature. The complete test and evaluation is contained in Appendix G.
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Figure 24 Post Test Teardown of the Urine Separator Shbwing the
Inlet Housing and Pitot Tube with No Urine Deposits
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Figure 25 Post Test Teardown of the Dual In-line Check Valve With
No Evidence of Foreign Debris or Urine Deposits
Figure 26 Post Test Teardownof the Check Valve Showing a
Clean Seat, Spring, and Poppet
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IFigure 30 Post Test Examination of the Separator Drum
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Microbial Air Sampling of the Urine Separator with Pretreat - During the
operation of the portable urine collection test rig in the men's bathroom, it was
decided to conduct a microbial air sampling survey of the pretr'eat test. On 25
and 27 April 1995 several air samples were taken at three locations in the air
side of the urine collection rig. Data indicated that air entering the portable urine
collection test rig in the bathroom, which contained upwards of 192 CFU/M 3 was
reading less than the detectable level of 12 CFU/M 3 at the outlet of the separator
fan. The complete test and evaluation are presented in Appendix H.
Oxone/PEG Tablet Long Term Storage
A test was conducted to determine the long term storage stability of the Oxone/
PEG tablets. Several tablets were processed on 12/6/94 and analyzed for the
percentage active compound (KHSO5) in the tablet. At this point in the program
the tablets were processed with 10% PEG which would relate to the same
percentage reduction from the maximum of 43% active component per the
Oxone MSDS. The theoretical maximum active component of a 10% PEG tablet
would be 39.7%. Table D shows the results for tablet storage with 10% PEG.
The "bulk" analysis which takes a complete tablet which is ground up to a
uniform mixture and then analyzed. The bulk analysis appeared to provide more
consistent results than the "center" or "surface" analysis. Later in the test
program during the actual urine collection test the PEG percentage was reduced
and finally standardized at 3.5%. For this configuration a new group of tablets
were set aside for a second long term storage test which started on 23 February
1995 and the results are also shown in Table D. The results show a high degree
of stability over the storage period from 2/23/95 to 5/2/95.
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Table D UPIS Oxone/PEG Pellet - Long Term Storage Study
Start Date = 12/6/94
Bulk = 26 1°4 KHSO5
Surface = 38 8% KHSO5
Center = 31 7% KHSO5
First Sample = I/I 9/95
Open Air Storage
Bulk = 26 5% KHSO5
Surface = 38% KHSO5
Center = 268% KHSO5
Plastic Bag Storage
Bulk = 26 5% KHSO5
Surface = 34 3% KHSO5
Center = 27 0% KHSO5
Glass Vial Storage
Bulk = 24.5% KHSO5
Surface = 257% KHSO5
Center = 25 7% KHSO5
Second Sample = 2/20195
Open Air Storage
Bulk = 26 5% KI-ISO5
Surface = 37 2% KI--ISO5
Center = 25.9% KHSO5
Start Date = 02123/95
Bulk = 33 2% KJ-ISO5
Plastic Bag Storage
Bulk = 26 3% KHSO5
Surface =33 0% KHSO5
Center = 25.8*/, KHSO5
Glass Vial Storage***
Bulk = 255% KHSO5
Surface = 28 9% KHSO5
Center = 25.7% KHSO5
First Sample = 03121/95
Open Air Storage
Bulk = 33.8% KHSO5
Plastic Bag Storage
Bulk = 330% KI-ISO5
Glass Vial Storage
Bulk = 33.0% KHSO5
Second Sample =05102/95
Open Air Storage
Bulk =320% K.I--ISO5
Plastic Bag Storage
Bulk = 33.2% KHSO5
Glass Vial Storage***
Bulk = 33.1% KHSO5
*** Significant amounts of moisture can be observed on the inside walls of the glass'vials.
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CONCLUSIONS
The prototype urine pretreat prefilter which contains several solid Oxone tablets
provided a safe, convenient, simple and reliable method of incorporating the
Oxone pretreat into a two-phase urine/air flow stream in a microgravity. The
preferred concept of the trade study was developed into the prototype version
with the proper quantity of Oxone in one pretreat/prefilter assembly for routine
changeout by an astronaut. The long term urine collection test conducted with a
flight type urine separator demonstrated the actual use of the urine pretreat
prefilter. The fnal tablet formation and percent of PEG binder met the primary
goal of controlling the primary goal of controlling the dissolution rate to maintain
an average of just slightly higher than 5.0 grams of Oxone per liter of urine.
A secondary goal that was met was demonstrated by a post test teardown of the
hardware and plumbing after processing a total of 342 liters of urine over a
seven (7) week time period. A visual examination indicated the internal wetted
surface areas were as clean as the initial assembly with no urine deposits. The
Oxone pretreat alone has sufficient acidity and antimicrobial control to maintain
proper hardware cleanliness upstream of the H2SO 4 injection point. An
additional Oxone concentration test conducted demonstrated that microbial
control and urine precipitate control could be maintained with average levels of
Oxone down to 3 - 3.5 grams per liter.
Another advantage of the Oxone as demonstrated by this program is that the
high degree of antimicrobial control is also maintained in the entrainment air
stream. Incoming air which had readable CFUIM 3 values if 193 were reduced
within the separator to less than the detection limit of 12 CFUs/M 3 at the
separator fan outlet. This would greatly reduce the bacteria load on the
downstream odor/bacteria filter.
RECOMMENDATIONS
Based upon the successful completion of the first phase of the Urine Pretreat
Injection System test program, the following recommendations are being made:
A second continuation phase of the Urine Pretreat Injection Test
Program should be conducted to include the effect of other pretreat
chemical (H2SO4).
Consider the possibility of using the developed Oxone Urine Pretreat
Prefilter in the Space Station stage 10 testing at NASA/MSFC in lieu of
the present liquid Oxone Injection System.
• Consider using the solid Oxone tablet approach in the Shuttle WCS to
minimize urine deposits buildup and post flight maintenance.
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Trade Study
Appendix A
A-1
Trade Study Objectives
Toreview various methods of injecting
OXONE ® into the C/US urinal upstream of
theseparator.
_, To select a method for prototype and test.
A-2
Selection Criteria
• Simplicity of Design
• Simplicity of Use
• Manufacturing Cost
• Handling Ease
• Safety
• Reliability
• Ease of Maintenance
• Maintenance Time
• System Envelope
• . System Weight
• Logistics Supplies Envelope
• Logistics Supplies Weight
• Usability in ISSA C/US
.• Material Compatibility
• Development Risk
• Development Cost
• Air Flow Impedance
• Power Consumption
A-3
>
I
• • e
m-J C_
l,--_e
o
0 _ 0
<
j-,._ •
0
0
0
0 _
"13
0
Initial Concepts...
• Solution Based Systems - introduce an Oxone/water solution into the
urinal either automatically with pumps and injectors, or manually with
a squeeze bottle. •
• Solid Based Systems - introduce an Oxone/binder solid into the urinal
in an active or passive manner. Solid designed to dissolve per
micturation or over 24 hour period.
• Powder/Granular Based Systems -introduce an Oxone powder or
grains to the urine stream in an active or passive manner. Per
micturation or 24 hour doses possible.
• Paste Based Systems - introduce an Oxone paste to the urine stream,
either automatically or manually, via a squeeze tube or syringe.
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... Initial Concepts.
)xone Pretreatment
Systems
I_ Based
-- Auto Mix/Dispense
(baseline system) •
-- Portable Tank,.
Auto Dispense
-- Squeeze Bottle,
Manual Dispense
-- Ventud FIo_
Solid
Based
- Manual Pill
-- Auto Pill
-- Pills in Filter
-- Quilted Pills
-- Rods in Filter
-- Pills on String
-- Dissolving Ring
Powder/Gr
Based
-- Manual "Tea Bag"
-- Auto ''Tea Bag''
-- Filter "Tea Bag"
(Integrated)
Screw Feeder
Paste
Based
Paste in Tube
- Manual
- Automatic
- Variations
A-6
Selections for Further Evaluation:
Quilted Pills
Pills in Filter
_, "Tea Bag" Integrated Filter
Dissolving Ring
4, Paste System
Auto Pill Injection
Rods in Filter
Automatic Solution Injection
A-7
Pills in Filter
i Pros:
- simple design
i Cons:
- high A P.
Conclusion - high bulk volume
of pills required for 24 hr
supply of Oxone will create
excessive air flow obstruction.
A-8
Quilted Pills
Pros:
- may reduce pressure drop
potentail over pills-in-bag
concept.
Cons:
- requires long filter.
- complicated+ filter sock
Conclusion- the number of
pills required for 24 hr supply
would make the filter
prohibitively long.
P O'S,?.
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"Tea Bag" Integrated Filter
Pros: ?
C on s: _ ?/_
I
, I
- dusting potentail _,._ ,_
g'J
- difficult to achieve _ _[._._ F,,_-?
dissolution over 24 hr ,, ,'
period. _;_ __---, e°'"_o,
I
- high AP or long filter :,_ ,_;
required for 24 hr design, t_
I t
S
\ /
• Conclusion- this method has no "-_-"
outstanding features which
would dictate its use.
A-IO
Dissolving Ring,,"
• Pros:
- reduces AP problems
associated with other solids
based concepts.
Cons:
- increases urinal housing
envelope.
- fragile form of solid,
difficult to insert in urinal.
_, Conclusion - negative aspects
of this concept outweight the
AP benefit.
A-11
Paste System
Pros:
- per micturation dosage.
i> Cons:
- requires paste development.
- back contamination prone.
i> Conclusion- paste development
risk and likelyhood of
contamination problems make
this concept undesirable.
I
I
I
I
1
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Auto Pill Injection
Pros:
4
- per micturation dosage.
* Cons:
- relatively complex system.
Conclusion - this concept
doesn't offer any substantial
benefits that would offset its
cost & development risk.
!/
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Rods in Filter
Pros:
- simple design.
- less AP than other solid
concepts.
Cons:
- small AP, but acceptable.
Conclusion - this concept offers
benefits of simplicity in design
and use which out-weigh the
small flow impediment. This
concepts should be compared to
the baseline concept.
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Auto Solution Injection
(Baseline Concept)
Pros:
- per micmration dosage.
- no AP problems.
4_ Cons:
- complex system.
- substantial development
risks.
Conclusion - this system is
complex and costly, but may be
able to take advantage of
Russian designs already
developed.
INJ_¢I_
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Final Comparison
Original Baseline System (Automatic
Solution Injection Systems)
Passive Solid Oxone System
(Rods in Filter)
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Passive Solid System
(Typical)
SEC!TION A-/_
SCALE. I. 000
_\\\\-,,'q .... i_
SECTION B-B
SCALE 1.000
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Comparison...
Auto Solution Injection Vs. Passive Solid
Criteria Auto Soln. Inj. Passive Solid
Simplicity of Design Complex Very Simple
Simplicity of Use
Manufacturing Cost
Handling Ease
Safety
Reliability
Ease of Maintenance
--.lt • -'--_.A_ r'r_-*-- _
System Envelope
System Weight
Simple Simple
• - J ...... I- .......
Easy Easy
Safe Safe_
Reliable More Reliable
I._tSt
• o_t/, . 'dn_,,,. ,,. No Maintenance Req
T .... U_. L__, Tnfr ........ _[_,7.3
Large It, None
Heavy _. Essentially None
A-19
...Comparison
Auto Solution Injection Vs. Passive Solid
Criteria Auto Soln. Inj. i Passive Solid
.......................................................................................................................................................................................................... i ................................................
Logistic Supply Envelope _ $',_,_1t_ i .$mald $,'_O._I
Logistics Supply Weight ]
_,,,L 3 hi lbbA k..,/Ub !i
Material Compatibility I
Development Risk
Development Cost
Air Flow Impedance
_r _t_,_ ]_J_., _ _.
usaoie ' " -t:tsable-
No Problems Expected No Problems Expected
High Low
High Low
None Higher, but Acceptable
A-20
Conclusions &
Recommendation
A 24 hour, filter-integrated solid Oxone
pretreatment system has allthe benefits of an
automated solution injection system without the
associated complexity, weight, envelope, high
development cost & risk, and high manufacturing
cost.
HSSSI recommends the development and testing
of the "Rods in Filter" type Oxone pretreatment
system.
A-21
Prototype Hardware Drawings
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PRODUCTSPECIFICATION
PRODUCT NAMe: "OXONE" MONOPERSULFATE COMPOUND
Number: 3611
SIMILAR NAMES : Potassium Peroxymonopersulfate
Potassium Monopersulfate
Property
J_ES SPECIFICATIONS:
Units Minimum
DATE ISSUED: 02/25/93
DATE SUPERSEDED: 05/22/89
Typical Test
Maximum Analysis Method
Active Oxygen (%)
Particle Size (%)
Thru USS #20 Sieve
Particle Size (%)
Thru USS #30 Sieve
Particle Size (%)
Thru USS #I00 Sieve
Particle Size (%)
Thru USS #200 Sieve
Particle Size (%)
Thru USS #325 Sieve
Water (%)
4.5
i00
95
5 35
i0
5
0.i
4.7 07000.475.04.M_
i00 O7000.295.01.ME
i00 O7000.295.01.M!
20 07000.295.01.MZ
5 O7000.295.01.M_
2 07000.295.01.M_
0.04 07000.570.01.M_
APPEARANCE: White, granular, free-flowing powder.
OTHER INFORMATION: Strong, odorless oxidant.
PHYSICAL DATA:
Property Typical Value
Molecular Weight
Potassium Monopersulfate (KHS05)
B',ik Density,
ib/ft3
g/cm3 (Mg/m3)
pH @ 25C (77F)
1% solution
3% solution
Solubility g/100g H20, 20C (68F)
(t)
614.7
44.7
72-79
1.15-1.27
2.3
2.0
25.6
For Further Information,
DuPont Company
Du Pont Chemicals
Wilmington DE. 19898
800 441-9408
Contact:
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DuPont Specialty Chemicals
DATA SHEET
OXONE Monopersulfate Compound
OXONE ° Monopersulfate Compound is a white, gran-
ular. free-flowing powder ideal for applications reclumng
a strong, oddness oxtdant. This perox'ygen compound is
particularty useful in formulated specialty products such
as denture cleaners, swimming pool products, laundry
bleaches, scounng powders, and bowl cleaners. OXONE
is also used as a selective oxidant in the manufacture of
organic chemtcals and as a processing aid in repulping
internal broke or a secondary fibers furnish.
OXONE is a triple salt with the formula 2KHSO_
• KHSO,,KzSO,. The active component, potassium
monopersulfate, has the chemical structure:
O
II
K--O--S--O--O--H
II
O
The physical properties and typical analyses of OXONE
are shown in Table I.
Solubility
OXONEis very soluble in water as shown in Table II. This
excellent solubility offers a distinct advantage over less
soluble dry oxidants, such as sodium perborate, particu-
larly at relatively low temperatures. At 20°C, the solubility
of OXONE in water is greater than 25 weight percent.
Water-ethanol, water-acetic acid, and water-ethanol-
acetic acid mixtures are good solvent combinations when
soivents other than 100% water are desired.
TABLE I
DU PONT OXONE _ PHYSICAL PROPERTIES
AND TYPICAL ANALYSES*
Molecular Weight 614.7
Ac",_-veOxygen, % nun. 4.5
% average analysis 4.7
% _eoratmal (tnple salt) 5.2
Active Comoonent (KHSOs), % rain. 42.8
Bulk Density, g/cr_ (Mg/rn_) t. 12-1.20
Ib/tt= 70-75
Partcle Size through USS #20 Sieve. % 100
through USS #200 Sieve, % max. 10
(aLso see Table III)
pH 25"(3 ('/"r F')
1% solution 2.3
3% solution 2.0
Solubility g/100 g HzO, 20"C (68°F ") 25.6
(aLso see Table II)
Mo_tura Content, % 0.1
Stability, % ac'c,te oxygen Io,s_rno_ < 1
Standar0 Electrcxle Potentzal (E°), ve_ls -1.44
Heat of Decomlx_s_on, kJ/kg 251
Blu/lb 108
Thermal Concluctivity, Wlm,,,K 0.161
_Z'F 0.093
•Thi= raisegr_= ty_ pml_mm=I_==¢1_=_hB=mcm_
_ormance. Ou Pont Ode=no¢roam _ e=anM=¢r _NKI
• Rig. U.S. Pit _ Tin. Off.. Du Po_ Corn p,lmy. OXONE • Monooer_.ulfa, le
_n¢l _ made otW I_ Ou Pont
NOTICE: OXONE _ MONOPERSULFATE COMPOUND CAUSES IRRITATION.
See Personal Safety and First Aid on page 3.
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TABLE II
SOLUBILITY OF OXONE "_MONOPERSULFATE
COMPOUND IN WATER
Temperature
°C °F g QXQN_IO0 g H20
20 68 25.6
27 80 26 8
49 120 30.0
60 140 31.5
71 160 33.5
TABLE III
TYPICAL PART]CLE SIZE ANALYSIS
OF DU PONT OXONE'*
MONOPERSULFATE COMPOUND
U.S. Screen Approx. Weight
Size (Mesh) % On Screen, Cumulative
30 1
70 68
100 84
200 98
325 T00
Stability
Terr_erature and DH can affect the slaDility of solutions of
OXONE • Monol:_ersultate Compouna (Figures 1 and 2).
At pH values Oelow 6 and above 12, solutions of OXONE
are retatively stal_le; however, at pH 9 a point of mm_mum
stability exists. At pH 7.5 or lower, active oxygen exzsts as
HSOs-, while at pH 12 the act=re oxygen species is SOs'.
Between pH 7.5 and 12 both iomc species exist in
solution and minimum stability corresponds to equal
concentrations of HSOs- and SOs'.
OXONE solutions are not as sensitive to trace metal
impunties as most peroxygen compouncls. However,
cot_lt, nickel, copper, and manganese ions do catalyze
the decomposition o! OXONE with the evolution o( oxy-
gen gas.
CHEMICAL PROPERTIES
Oxidation Potential
The standard electrode potential (E°I of OXONE is
-1.44 volts for the reaction:
HSO4- + HzO _ HSOs- + 2H* + 2e-
This high potential suggests many room temperature
oxidations with OXONE: halide ion to halogen, ferrous
ion to femc, manganous ion to mangantc, and hydrogen
peroxide to oxygen.
Formulation
OXONE is compatible w_th anhydrous sails such as
sodium sulfate, sodium tnpolyphosDhate, teu'asoclium
pyrophosphate, sodium carbonate, and sodium metasili-
cate. Conventional surfactants such as alk'yl ar_ sullon-
ates and limited quant_es of nonionic detergents may
also be used in lormulatJons of OXONE.
RGURE 1 FIGURE 2
STABILITY oFA 1% SOLUTION OF EFFECT OF pH* ON STABILITY OF A
OXONE _ AT VARIOUS TEMPERATURES 3% SOLUTION OF OXONE* AT 32°C (89,6°F)
o '_ o
2 4 6 8 10 12 14 16 18 2 4 6 B 10 12 14
° pH adjusted _ KOHo
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CHEMICAL REACTIONS
OXONE • Monopersulfate Compound reacts w_th many
organJc compounds _n aqqueous or solvent-water solu-
tions to convert:
1 Phenol to ClUlnone (EIbs persulfate oxidation).
2 Cyclic ketones to lactones.
3. Toluene tO benzoic acid.
4. Dioheny_methane to benzo0henone.
OXONE can convert:
1. Olefins to glycols or glycol esters, depenozng upon the
solvent system selected.
2. Cyctohexene to trans- ratherthan c=s-cyclohexanediol.
3. Primary aryl amines to mtroso combounds.
4 Pyndine to pyndine-N-ox=de by a slurry of OXONE in
gtacial acetic acid.
Epoxaaes nave not been _solatea from reactzon systems
of OXONE and otefins.
OXONE can initiate the free radical polymenzation of
typical vinyl monomers such as vinyl acetate, ethyl acry-
late, and acrylonitrile.
An atypical reaction is the conversion of toluene to benz_/I
halide by heating with a dry mixture of OXONE and
sodium chloride or sodium bromide.
Detailed information on the use of OXONE in organic
reactions appears in "Oxidation of Organic Substances
by Potassium Perox-ymonosulfate" by R. J. Kennedy and
A. M. Stock, J. Org. Chem., 25, 1901 (1960).
PERSONAL SAFETY AND FIRST AID
Health Hazards
OXONE Monopersulfate Compound has a low order of
toxicity when taken internally. The approximate lethal
dose (ALD) for rats is 2250 mg/kg.
OXONEis =rotating to the eyes, skin, nose, and throat due
to its acidity and oxidizing properties, and may cause
allergic reactions in sensitive individuals. Du Pont
o¢_serves an airborne exposure limit to OXONE dust of
1 mg/m 3, 8-hour time weighted average.
Safety Precautions
Persons handling OXONE should avoid contact with
skin, eyes, or clothing. Avoid breathing dust, Wash
thoroughly after handling and launder contaminated
clothing before reuse. Exl3osure can be minimized by
providing adequate ventilation and by weanng rubber.
or plastic-coated gloves and chemical safety goggles
when handling OXONE.
Site Facilities
The following safety eclu=pment should be easily acces-
sible in all areas where OXONE is nanclled or stored:
Safety Showers with clu=cX opening valves that stay
open. Water should be supplied through insulated
lines.
Water Hydrant and Hose or other means of flushing
spills w,th _arge volumes of water uno'er low I_ressure.
Eye Wash Fountains or other means for washing the
eyes with a gentle flow of tap water.
First Aid
In case of contact, immediately flush eyes w_th ptenty
of water for at least 15 minutes. Flush skin with water. If
inhaJed, remove to fresh mr. Call a pt_ys_c_an.
APPLICATIONS
The high oxidation potential of OXONE suggests _ts
application =n vanous cleaning compounds where _t is
desired to eJiminate oxidizable discolorations. OXONE
can be blended with a w_de vanety of conventional
additives including sodium perborate monohydrate,
diethyfenetnamme pentaacettc acid (DTPA), tetrasodium
pyrophosphate, sodium tripolyphosphate, sodium meta-
silicate, sodium carbonate, sodium bica_onate, sodium
sesquicarl3onate, citnc or tartaric acid, wetting agent or
detergent, sodium sulfate, and fragrance. Formulations
can be sol(t as free.-flowmg powders or can be tablefted.
Since OXONE is acidic, it is usually buffered to near
neutral or alkaline pH when compounded into cleansers.
Formulations of OXONEcontaining chlonde ions can be
used to generate low concentrations of active chlonne in
cleaning systems. The actwe chlonne can be present as
hypochlorous acid or hypoctllonte ion, depending on the
system pH; it is necessary 1o use sufficient at._aJi in the
formulation to avoid generation of elemental chlonne,
which is a highly toxic gas. OXONEthat is not converted
to active chlorine will cont2nue to function as acttve
oxygen.
The above addi_ntes must be anhydrous; otherwise,
undesirable reactions may occur between the acidic
solution of OXONEand the additives.
Denture Cleaners
The properties of OXONEhave been shown to be par-
ticularty adaptable to denture cleaner formulations be-
cause of its ability to decolonze food and other organic
stains. To obtain the desired pH and cleansing proper-
ties, a general purpose denture c.Jeaner formulation should
contain at least 2S% OXONE, and any of the additives
listed above.
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Industrial/Institutional Laundry Bleach
OXONE z Monobersulfate Compound can be reaody
formulatecl with conventional anhydrous alkahne fillers
into a stable, free-flowing, dry bleach. In formulating a dry
bleach with OXONE. sufficient alkali must be used to
ensure a pH of 9-10 in the laundry use. A suggested
mixture of 35% OXONEand 65% light granular soda ash
is simpte, low cost, with low bulk density, and has an
attractive aD!oearance. In use. a concentration of at least
25 bPm of actwe oxygen _s preferable in the laundry
solution (abprox_mately 4 ounces of the 35/65 mixture
per 18 gattons ot water wfll y_etd 25 ppm active oxygenL
For stain removal, concentrations as high as 200 ppm
aclive oxygen _n hot water may be used. OXONE must De
dissolved pnor to contacting fabncs as Jt may cause dye
damage under some conditions.
Bowl Cleaners
Toilet bowl cleaners for home use are composed bnma-
nly of sodium bisulfate with small amounts of detergent,
fragrance, and corrosion tnhit:)itor. The solution 9H of
these cleaners m use =s 1-2. Functions of the acidic bowl
cleaners are soil and stain removal. These product
characlenstics may be enhanced by including 1-3%
OXONE in the bowl cleaner formulation.
SWIMMING POOL/SPA PRODUCTS
Swimming Pool/Spa Oxidizer ("Shocking Agent")
OXONEMonopersulfate Compound can be used as an
auxiliary oxidant (shocking agent) in swimming pools
and spas for the purpose of reducing the orgamc content
of the water. The treatment, which is generally recom-
mended at two-week intervals or whenever cJoucliness is
present, increases the clarm/of the water and reduces
eye bum and chlonne odor by destroying chlorammes.
The excellent solubility of OXONE makes it ideal for
addition to pools and spas by broadcast or wa the filter
basket.
Unlike chlorine-based shocking agents that super-
chlorinate the pool, OXONEdoes not increase the chlo-
rine level. Therefore the pool need not be closed except
for a short penod to fully circulate the OXONE.
In this appJication, OXONEis not a disinfectant and must
be used in addition to an EPA (FtFRA) registered disin-
fectant.
OXONFJSodium Bromide Disinfection
OXONE can also be used as one part of a two-part
disinfectant system for spas and hot tubs with soclium
bromide. OXONEoxidizes bromide to bromine, winch =s
present as the active disinfectant HOBr in the pH range
usually found in spas and hot _bs. This two-part disintec.
rant system has been EPA (FIFRA) registered by several
manufacturers of swimming poor c_emscats: sucn regis-
tration ts necessary before offenng d_smfectants for sale
,nme United States. Other funsO_ctlons may also require
additional registrations
Since the organic toading of a spa or hot tub is oflen
greater than that of a swimming pool, chlonne-basea
disinfectants have a tendency to cause cloudiness and
chlonne odor because ol the formation of stable chlora-
mines. Bromine-based disinfectants form ioromammes,
which are unstable and are recogmzed as good disinfec-
tants. Bromine-disinfected spas have lower odor, less
cloudiness, and cause less eye =rntat_on tr_an chlonne-
d_sinfected spas.
For this use, it may be desirable to neutralize the ac=diW
of OXONEby formulation w=th an anhydrous alkaline salt
such as sodium carlDonate. A mixture of 80% OXONE/
20% sodium carbonate by wmght gives a neutral pH.
Dilution to control dosage may be done with anhydrous
sodium sulfate.
PULP AND PAPER INDUSTRY
OXONE Monopersulfate Compound can be used as a
processing aid in repulping internal broke or a secondary
fibers fumish. Paper products containing polyamide epi-
chlorohydrin wet strength resins can be effectively
repulped to make the same grade paper. OXONE has
been demonstrated on a vanety of sanitary, food, pack-
aging, and specialty papers containing wet strength resin
and made from different furnishes. In addition, because
of its dye destruction capability, OXONE can also be
used to repulp certain colored papers.
Unlike chlonne-based reputping agents, OXONE does
not prociuce AOX or other chlonnated organics. It also
does not degrade the fiber or darken mechanical pulp, It
is easier to handle and does not require any additional
storage or delivery equipment. Under optimum condi-
tions, OXONE reacts rapidly, thereby reducing the
repulping time and increasing the productivity of the
pulper. It is effective under commonly found pulping
conditions.
TEST METHODS
Active OxygeNActive Component
The active oxygen in OXONE Monopersulfate Com-
pound or in mixtures of OXONEwith other materials can
be determined by using the standard iddometrictitration,
Iodine released from an acidic potassium iodide solution
by the active oxygen in OXONEis titratecl with standard
sodium thiosulfate to a colorless end point. The following
method is suggested.
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1 Take four samples, one from each quarter of _he
matenal to De analyzed.
2. Blend samples by using a Small blender or rolling Jna
container for about 5 minutes.
3. Empty the blenOed sample onto a glass pte plate or
flat dish and take small samples at random to obtain
0.5 g for analysis
4. Weigh the sample to the nearest 0.001 g.
5. In a 250 mL beaker equipped with stirrer add 50 rnL
distilled water. 5 rnL of 20% sulfuric acid, and 10 rnL
20% potassium toe=de solution. Then add the weighed
sample, and sttr to completely dissolve ft.
6. "i3trate w_th 0.1 Nsodium tmosulfate solution to a color-
less end point that persists for 30 seconds. (Starch
indicator ShOuld be used for enhancement of the end
point.)
7. Calculate:
% active oxygen =
rnL thtosulfate x N x 0.008 x 100
sample weight (grams)
where N is the normality of the sodium thiosulfate.
% active oxygen% active component (KHSOs) =-
0,1053
Moisture Content
I. Using the sampling procedure above, weigh 10 g
(,:1:0.01 g) in a tared aluminum dish.
2. Dry for 30 minutes in a 65°C +0.5°C oven.
3. Cool in a desiccator and weigh.
4. Calculate:
% motsture original wt. - dry wt.= x 100
onginal wt.
SHIPPING CONTAINERS
A moisture banter package is recommended for formu-
lated mixtures of OXONE. Du Pont ships OXONE in
multJwalled, moisture-resistant, 25 kg (55.1 Ib) net paper
bags and in lined, 907 kg (2000 Ib) bulk bags. OXONE
Monopersulfate ComI_ound is not regulated as a hazard-
ous matenal by the Department of Transportation as of
December 1987."
• _ tO ¢f_,nglng govemmlml tt_u_atK:e,s s.u¢_ as tttos,e OI _ Department
(_ TtaP_t=on, Oepli"o'ne_ of Lab,or'.U.S. En_mttmecclaJ PnoteIbon
Agm'tCy. atlO the FOO0 Ir_ On.R ;uJrmm_ra_on. rete,"e_cL_ r,erem may De
S,_:)4fSdl<Se_. The Lz._er _ C_tSUIt atta follow t,l'le ¢u n'llt'_ govoffu1'_flt,l_
f_ju_tt)ons, su_ as H=_u_ Ctas._caucm. LaDelJn_, Foo_ Use Clear-
lu'mm=. WoOer ExC<rsure t._,_l_'_, aria Waste Dtsoo_aJ ProceOuras for
the I:m:X:IuCt ClesC_Cx_ m _S _enlture.
STORAGE AND HANDLING
Precautions in Use
OXONE • Monopersulfate Compound _s a moderately
strong oxidizer. It should be stored _na coot. d_ location,
away from combustible materials.
The mIxture of OXONE w_lh cornpounOs contain=rig ha-
tides or active halogens can cause release of the respec-
t=re halogen ff moisture _s present. For example, rn_x-ture
w_th soOlum dichloroisocyanurate Or with Socilum chiP-
nde can cause retease of ci_tonne gas: mixture w_th
cyamdes can cause retease of hydrogen cyanide gas;
and r_eavy metal salts such as those of cobalt, nicX;et,
copper, or manganese cause the evolution of oxygen.
Like all other peroxygen corn0ounds, OXONE under-
goes very stow aecornpos=tton in storage, which also
liberates heat. In order to provide sufficient surface area
to dissipate the small amount of heat generatecl. OXONE
should not be stored or processed in large masses
exceeding a cuPe 4 ft on each side (64 ft_) or approx=-
rnately 4500 Ib OXONE. Storage of quantities of OXONE
_nexcess ot this limit can lead to runaway decornDos[tion
with liberation of large amounts of heat and oxygen gas.
If the internal temperature of the material exceeds 3(X]°C
(m.p. KzSO,), the matenal may fuse and could generate
SO_ or SO_ gases.
Pallets of OXONE(less than 64 fl_/pallet) can be stacked
if there are 2-3 inches of air space ioetween pallets.
Grinding or intensive mixing may generate sufficient
heat to fuse OXONE and cause the ignition of oxidizable
material if present.
Spills
Spills and sweepings should be removed and the area
thoroughly washed with water.
Dry Stability
When stored in a cool, dry place, OXONE is an excep-
tionally stable peroxygen compound. The rate of decom-
position at these storage conditions should be less than
1% per month of contained actwe oxygen. Any mixture
should be tested pnor to packaging.
Materials of Construction
The pnmary consideration in choosing eduiprnent for
handling OXONE and solutions of OXONE is to prevent
contamination of the product with rust or other ca_lylx:
metals. Thus, stainless steel, porcelain, glass, and many
plast=cs may be considere¢[ suitable. Containers and
small packages for OXONEshould be of moisture Darner
construction.
The use of OXONE and sodium chlonde in formula_ons
may cause mild corrosion problems, but the use of
sodium nitrate or other chloride corrosion inhibitors w_il
minimize this problem.
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Du Pont Chemicals
Wilmington, Delaware 19898
U.S. Sales and Services
For placing orders or requesting additional product inforl"nat=on,
please use our ¢onvement 24-hour toll-free telephone number.
If you prefer, you can wnte to us.
By Phone
Toll free in continental U.S.
(excel_t Delaware)
1-800-441-9442
In Delaware
(302) 774-2099
By Mail
Du Pont Chemicals
Customer Servnce Center
Wilmington, DE 19898
International Sales Offices
ASIA PACIFIC
Du Pont Japan Ltd.
10-1, Toranomon 2-¢home
Minato-ku
Tokyo 105, Japan
3-585-5511
Du Pont Far East, Inc.
Maxwell Road
P.O. Box 3140
Singapore 9051
273-2244
Du Pont Asia Pacific Ltd.
Du Pont Chemicals
P.O. Box TST 98851
Tsim Sha Tsui, Kowtoon
Hong Kong
734-5345
CANADA
Du Pont Canada Inc.
Du Pont Chemicals
P.O. Box 2200, Streetsvtlle
Mississauga, Ontario
L.5M 2H3 Canada
(416) 821-3300
EUROPE
Du Pont de Nemours International S.A.
2, chemin du Pawllon
P.O. Box 50
CH-1218 Le Grand Saconnex
Geneva, Switzerland
(22) 717 51 11
LATIN AMERICA
Du Pont Chemicals
Latin America Sales Office
Wilmington, DE 19898
(302) 774-3403
"m ====
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"OXONE" MONOPERSULFATE COMPOUND
CHEMICAL PRODUCT/COMPANYIDENTIlqCATION
Material Identification
"OXONE" is a registered trademark of DuPont.
Corporate MSDS Number' 0U005614
CAS NumDer 70693-62-8
CAS Name POTASSIUM HYDROGEN PEROXYMONOSULFATE
SULFATE
Grade TECHNICAL
Tradenames and Synonyms
POTASSIUM PEROXYMONOSULFATE
Company Identification
MANUFACTURER/DISTRIBUTOR
DuPont
1007 Market Street
Wilmington, DE 19898
PHONE NUMBERS
Product Information 1-800-441-9442
Transport Emergency CHEMTREC: 1-800-424-9300
Medical Emergency 1-800-441-3637
COMPOSITION/INFORMATION ON INGREDIENTS
Co=ponents
Material CAS Number
POTASSIUM PEROXYMONOSULFATE 10058-23-8 43
POTASSIUM BISULFATE 7646-93-7 23
POTASSIUM SULFATE 7778-80-5 32
MAGNESIUM CARBONATE 546-93-0 2
Co_=nu_)
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HAZARDS ID_CATION
Potential Health Effects
Causes skin, eye, nose, and throat irritation. May cause
allergic skin reactions at high concentrations in sensitive
individuals. Ingestion may cause inflammation and damage to
the lining of the stomach, resulting in bleeding.
HUMAN HEALTH EFFECTS:
Skin contact may cause skin irritation with discomfort or
rash. Allergic skin reactions were observed at high
concentrations, but at lower concentrations of 12 ppm and
150 ppm, no allergic reactions were noted. Eye contact may
cause eye irritation with discomfort, tearing, or blurring
of vision. Inhalation may cause irritation of the upper
respiratory passages with coughing and discomfort.
Ingestion may cause gastritis possibly progressing to
necrosis or hemorrhage.
Individuals wlth preexisting diseases of the skin or
gastrointestinal tract may have increased susceptibility to
the toxicity of excessive exposures.
Carcinogenicity Information
None of the components present in this material at concentrations
equal to or greate r than 0.I_ are Iisted by IARC, NTP, OSHA or ACGIH
as a carcinogen.
FIRST AID MEASURES
# First Aid
INHALAT ION
If inhaled, remove to fresh air. If not breathing, give
artificial respiration. If breathing is difficult, give oxygen.
Call a physician.
SKIN CONTACT
In case of contact, immediately wash skin with soap and water.
Wash contaminated clothing before reuse.
EYE CONTACT
In case of contact, immediately flush eyes with plenty of water
for at least 15 minutes. Call a physician.
INGESTION
If swaIlowea, do not induce vomiting. ImmediateIy give 2 glasses
of water. Never give anything by mouth to an unconscious person.
Caiia physician.
(C_=nue_.)
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Flammable Properties
Will not burn.
Fire and Explosion Hazards:
Storage of large masses of "OXONE" can trap heat and lead
to ignition of paper bags. Grinding or intensive mixing
may cause ignition of oxidizable material present.
Extinguishing Media
Water.
Fire Fighting Instructions
None.
ACCIDENTAI RELEASEMEASURES
Safeguards (Personnel)
NOTE: Review FIRE FIGHTING MEASURES and HANDLING (PERSONNEL)
sections before proceeding with clean-up. Use appropriate
PERSONAL PROTECTIVE EQUIPMENT duping clean-up.
Accidental Release Measures
Sweep up. Flush area with low pressure water.
HANDLING AND STORAGE
Handling (Personnel)
Avoid breathing dust. Avoid contact with eyes, skin, or clothing.
Wash thoroughly after handling.
Storage
Store in a cool, dry, well-ventilated area. Stack on
pallets providing air space; closely stacked bags should not
exceed a 4 ft. (1.2 m) cube. Keep packages dry. Do not
store with combustible materials.
EXPOSURE CONTROLS/PERSONALPROTECTION
Engineering Controls
Use sufficient ventilation to keep employee exposure below
recommended limits.
Personal Protective Equipment
EYE FACE PROTECTION
Wear safety glasses. Wear coverall chemical splash goggles
and face shield when the possibility exists for eye or face
contact from airborne _aterial.
RESPIRATORS
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EXPOSURE CONTROLS/PERSONAL PROTECTION(c_=nu,_)
A NIOSHIMSHA approved air-purifying respirator with a
dust/mist cartridge or canister may be permissible under
certain circumstances where airborne concentrations are
expected to exceed exposure iimzts. Protection provided by
air purifying respirators is iimited. Use a positive
pressure air supplied respirator if here is any potentiai
for an uncontrolled reIease, exposure leveIs are not known,
or any other circumstances where air purifying respirators
may not provide adequate protection.
PROTECTIVE CLOTHING
Wear impervious clothing, such as gloves, apron, boots or
whole bodysuit, made of ruDDer, as appropriate. Leather
gloves may De used when handling dry materiai.
Exposure Guidelines
Exposure Limits
"OXONE" MONOPERSULFATE COMPOUND
PEL (OSHA) Particulates (Not Otherwise Reguiated)
15 mg/m3, 8 Hr. TWA, total dust
5 mg/m3, 8 Hr. TWA, respirable dust
TLV • (AGGIH) None Established
AEL * (Ou Pont) 1 mg/m3, 8 Hr. TWA
Other Applicable Exposure Limits
POTASSIUM SULFATE
PEL (0SHA) None Established
TLV (ACGIH) None Established
AEL ° (Ou Pont) 10 mg/m3, 8 Hr. TWA
MAGNESIUM CARBONATE
PEL (0SHA) 15 mglm3, total dust, 8 Hr. TWA
5 mglm3, respirable dust, 8 Hr. TWA
TLV (ACGIH) 10 mg/m3, torsi dust, 8 Hr. TWA
AEL * (Du Pont) None Established
• AEL IS Ou Pont's AcceptlDle Exposure Limit. Where governmentelly imposed occuDltionll exposure
limits which ere lower then the AEL are in effect, such limits snell tame precedence.
, i
PHYSICAL AND CtEMIC_ PROP_I3_
Physical Data
Boiling Point
Vapor Pressure
Vapor Density
Melting Point
Evaporation Rate
Solubility in Water
pH
Odor
Form
Color
Specific Gravity
Q 760 mm Hg Decomposes
Nil
Not volatile
Decomposes
(Butyl acetate = 1)
Not volatile
25.6 WT_ _ 20 C (68 F)
1_ solution = 2.3; 3_ solution = 2.0
Odorless
Granuiar; free flowing solid
White
1.1 -1.4
(Ccm_r_ed)
D-5
STABILITY AND REACTIVITY
Chemical Stability
Stable.
Incompatibility with Other Materials
The mixture of "OXON£" with compounds containing halides or
• active halogens can cause release of the respective halogen
if moisture is present. For example, mixture with sodium
dichloroisocyanuride or with sodium chloride can cause
release of chlorine gas; mixture with cyanides can cause
release of hydrogen cyanide gas; and heavy metal salts suc_
as those of cobalt, nickel, copper, or manganese cause the
evolution of oxygen.
Decomposition
Releases oxygen gas.
Polymerization
Polymerization will not occur.
TOXICOLOGiCAl INFOILM.ATION
Animal Data
Inhalation 4-hour LC50:>5 mg/1 in rats
Skin absorption LD50 : >11,000 mg/kg in rabbits
Oral LD50 : 2,000 mg/kg in rats
The compound is a severe skin and eye irritant, but is not a
skin sensitizer in laboratory animals. Single inhalation
exposures produced nonspecific effects such as weight loss
and irritation. Repeated inhalation exposures produced eye
irritation and reversible corneal damage. By ingestion, the
administration of large single doses produced nonspeczfic
effects such as weight loss and irritation as well as
gastric ulceration, necrosis, and hemorrhage. The compound
does not produce genetic damage in bacterial cell cultures.
ECOLOGICAL INFORMATION
# Ecotoxtcological Information
Aquatic Toxicity
Potassium Sulfate
96-hour Tim, bluegill sunfish : 3,500 mg/L
Magnesium Carbonate
96-hour LC50, species unidentified: >1,000 ppm
(C,oeanut.:t)
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DISPOSAL CONSIDERATIONS
Waste Disposal
Comply with Federal, State, and local regulations. If
approved, flush to sewer or waste treatment plant. Large
quantities should be neutralized with soda ash.
TRANSPORTATION INFORMATION
Shipping Information
NOT REGULATED AS A HAZARDOUS MATERIAL BY DOT OR IMO.
Shipping Containers
Multiwall Bags
Fiber Pack Drums
REGULATORY INFORMATION
U.S. Federal Regulations
TSCA Inventory Status Reported/Included.
TITLE III HAZARD CLASSIFICATIONS SECTIONS 311, 312
Acute : Yes
Chronic : No
Fire : No
Reactivity : No
Pressure : No
LISTS:
SARA Extremely Hazardous Substance - No
CERCLA Hazardous Material No
SARA Toxic Chemical No
CANADIAN WHMIS CLASSIFICATION:
D2B
OTHER INI_ORMATION
NFPA, NPCA-HMIS
NPCA-HMIS Rating
Health 2
Flammability 0
Reactivity 1
Personal Protection rating to be supplied by user depending on use
conditions.
Additional Information
For further information, see DuPont "OXONE" Monopersulfate
Compound Data Sheet,
(Co_anoe_}
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The data in this Material Safety Data Sheet relates only to the
specific material designate_ _erein anO aoes not relate to use in
com_ination with any other material or zn any process.
Responsibility for MSDS
Address
Telepl_one
# Indicates uogated section.
OuPont Chemicals
Engineering & Product Safety
P. O. Box 80709, Chestnut Run
WilmZngton, DE 19880-0709
302-999-4946
End of MSDS
D-8
Test Log and
Data Sheets
Appendix E
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Test Title
Urine Pretreat Injection System (UPIS-1) 30-day prototype evaluation test for oxone '_
introduction.
Test objective: The purpose of this test program is to evaluate the prototype solid
(tablet) injection method selected for introducing proper levels of
oxone safely ancl conveniently into a micro-gravity two-phase
urine/air intrainment collection system.
Test Hardware: Test equipment to be used is the Shuttle DTO two-phase unne
fan/separator with the clear lexan housing installed. The test
fan/separator will be installed in the portable unne collection test rig
(known as the VV_z.zon Wheels), which will be located convemently
in a men's bathroom in Building 1A at Hamilton Standard.
Also used will be the DTO flight type dual check valve,
which is located in the urine outlet line.
Test Setup: The portable urine collection test setup will be positioned in one of
the bathrooms to collect urine from volunteers on a real-time basas.
Fresh, warm urine will be processed immediately through the DTO
urine fan/separator and pumped into a downstream pressurized
accumulator. See Schematic in Figure 2. A prototype pretreat/
prefilter will be installed in the urine collection inlet
housing and will be changed on a routine time line. Provisions will
be provided for clownstream urine with dissolved oxone to be
stored and analyzed. An electrical block diagram is also shown in
Figure 4, which shows the basis electrical hookup.
Test Procedure: The detailed test procedure for the 30-day unne collection test _s
divided into several tasks, which include the following:
Test Rig Checkout - The portable urine test rig will be initially
checked out using water as a test media to verify that the
mechanical and electrical elements of the ng operate properly.
During this test the oxone pretreat-prefilter will not be used. The
checkout will also be used as a basepoint test to determine if any
degradation of the test hardware has occurred during the 30-day
tests. (A basepoint test will be conducted after completion of the
test before teardown). Data will be taken of various parameters of
the urine fan separator operation such as speed, output pressure.
and, etc.
Also, as part of rig checkout, a baseline of the dissolution rate of
the prototype pretreatlprefilter wilt be conducted. The latest verszon
of the prototype pretreat/prefilter will be installed in the inlet hose
and water will be introduced into the system at the same rate,
quantity, and cycle time as the previous laboratory dissolution rate
test procedure. This test will be conducted to determine if there are
any differences between the lab test setup and the portable urine
collection test set.
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®Figure 2 Schematic of Portable Urine Collection Test Rig
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Figure 4 Electrical Block Diagram for Wiz.z on Wheels UPtS Test
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User Instructions
1. Verify "ready to use" sign.
2. Life "anti-use' lid.
3. Verify two (2) green lights.
4. Do your thing!!
5. Close lid when done.
Note: This action will turn on the fan/separator
Note: This indicates that both fan and separator are at
operating speed.
If both green lights are not on:
• Do not use test item
• Close lid
• Use normal urinal
• Call Dr. Flush (x2166)
Note: This action will automatically provide an 80ml
H20 flush and shut down the fan/separator after a one-
minute fan dry-out cycle.
User Helpful Hints
• Please try to keep collection area clean
• Please only one cycle of the lid per use. (Extra cycles will offset test calculations.)
• If a line forms -- next user _s requested to wait until fan/separator shut clown prior to
retifting lid.
• If you goof, it will not be held against you, but please let Dr. Flush know so that the
test data can be properly compensated for.
• Your comments are welcome!!
Thank you very much
for your participation
Dr. Flush (x2166)
Figure 5 User Instructions
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Figure 6 Sample Data Sheet
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Test completion and tear dgwn
Upon completion of the 30-day urine collection test (or longer if
time and need allows) a post test base point test similar to the
pretest base point will be conducted using water. The pre and post
test data will be compared to determine any significant changes.
Also, the clear tygon tubes and the clear lexon housings on the
fanlsebarator will be wsually _nspected for evidence of
contamination or urine solids buildup. If required the fan/separator
witl be disassembled for further internal visual inspection along with
photographs.
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APPENDIX A
LAB PROCEDURES
Chemical Analysis of Pretreated Urine
The following analyses will be performed in the Chemical Analysis Laboratory.
Quantity: 200 mL
Container: Plastic Falcon Disposable Cup with Lid
Analyses:
pH: pH wilt be measured using an Orion epoxy-body electrode.
Conductivity: Conductivity will be measured using a YSI Conductivity Bridge.
Active Oxygen: Active oxygen content (or Oxone content) will be determined.by
titrating with sodium thiosulfate, This is the analysis procedure
recommended by DuPont. The analysis procedure is outlined
below.
Titration: Iodine released from an acidic potassium iodide solution by the
active oxygen in the Oxone is with standard sodium
thiosulfate to a colorless endpoint.
1. Use enough pretreated urine to contain approximately 0.5 g of
dissolved oxone. Weight to the nearest 1 rag.
. In a 250 mL Erlenmeyer flask, combine the urine sample, 5 mL of
20% sulfuric acid and 10 mL of 20% potassium iodide. Add two drops
of starch solution. Mix well.
3. Titrate with 0.1 N sodium thiosulfate to a colorless endpoint that
persists for 30 seconds.
4, Calculation:
% Active Oxygen = Q * N ° 0.008 * 100
M
Where: Q = Volume of sodium thiosulfate (mL)
N = Exact normality of sodium thiosulfate
M = Mass of sample (g)
% Active component (KHSOs) = % Active Oxy_gen
0.1053
F-IO
Oxone Concentration Evaluation
In Urine
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Internal Correspondence
March 28, 1995
SVME:3445
Memorandum to: D. Rethke
cc: J. Steele, J. Varsik, B Peyton
From: R. Marsh
Subject: Oxone Concentration Evaluation In Urine
The purpose of this memorandum is to report the laboratory findings for
the evaluation of Oxone® as a urine additive to control microbial growth
Introduction
Oxone® is a monopersulfate compound that has many applications where
a strong oxidant is required in cleaning and bleaching uses. The Oxone@ data
sheet is attached. This material is being evaluated as a pretreatment in the
International Space Station Alpha (ISSA) Waste Collection System(WCS) for
crew urine. Chemical treatment of urine will be required on ISSA to prevent the
development of undesirable noxious odors, proliferation of microorganisms, and
the prevention of urine salt formation. This study evaluated the effect of several
concentrations of Oxone® to control microbial growth in a pooled male human
urine.
The experiment challenged the urine with Pseudomonas aeruqinosa and
Pseudomonas cepacia test organisms. This was done to simulate a worst case
scenario which could simulate a crew member with a urinary tract infection or
any other event where microbes could be introduced to the WCS.
Oxone® was added to the urine at concentrations of 0.1,1.0,2.0,3.0,4.0,
and 5.0 grams per liter(gm/L). The target use concentration for Oxone® in the
WCS is 5.0 gndl.
The interest that initiated this study was how well will Oxone® control
microbial growth and will the 5.0 gmlL be adequate.
Results
The urine containing Oxone® and the challenge microorganisms was
maintained at ambient temperature and was assayed at time 0 and at 3 and 7
days, The urine containing Oxone® 0.1,1.0 and 2.0 gm/L showed no effect
controlling the microbial challenge and the population increased. At 3.0 gm/L
Oxone® there was limited control which allowed further microbial development,
The 4.0 and 5.0 gm/L Oxone® levels prevented microbial growth throughout the
test period. This data is illustrated in the attached graph and data sheet. The
attached photographs illustrate the various test concentrations and show the
G-2
effect of microbial control vs. no control. Photograph 1 shows the range of the
Oxone® concentrations (0 to 5 gm/L), effective microbial control can be seen in
bottles labeled 4.0 and 5.0. The bottle's label on the reverse side of the tape
label is clearly visible through the treated urine (no microbial growth). The urine
in the other bottles (0 to 3.0) is very turbid indicating no microbial control and the
labels can not be seen, bottle 30 shows partial m_crobial control. Photograph 2
shows these observations in greater detail.
The pH of these samples was measured on test day 11. The pH values
ranged from 8 94 for 0.1 gmtL Oxone® to 4.48 for 5_0 gm/L.
Discussion
This test evaluated Oxone® as a microbial control agent at six
concentration levels. Microbial control was attained at 4.0 and 5.0 gmlL in the
pooled male human urine. The Oxone® concentrations less than 4.0 grrdL were
not effective controlling microbes and high populations developed. The urine
collected on ISSA is planned to be processed on a daily basis. Therefore, the
Oxone® treatment at greater than 4.0 gm/L appears to be &dequate to control
microbes in the WCS.
This study was not able to observe urine salt formation since the urine
was collected and held for 18 hours at 4°C after collection and prior to use the
urine was filtered through glass wool to remove any precipitates. The test was
run at ambient temperature which would not be favorable for salt precipitation.
No urine salts were visible in the test bottles during the test period
Recommendation
Based upon this study Oxone® was shown to be effective at the 4.0 to 50
gm/L concentration in controlling microbes in human urine. This concentration
should be maintained throughout the WCS to prevent the development of
microorganisms that could pose a problem by generating odors or increasing the
microbe level within the cabin.
Prepared by: f_-,._ _'_ _-,_.J
Robert W. Marsh
Attachments:
Oxone® Data Sheet
Graph
Data Sheet
Photographs
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URINE PRETREATMENT INJECTION SYSTEM
OXONE AS A MICROBIAL CONTROL AGENT
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DATE DAYS
ON TEST
OXONE OXONE OXONE OXONE
0 0.1 1 2
02/24/95 0 6.80E+05 7.00E+05 3•00E+05 5.50E+04
02/27/95 3 4.00E+08 4.40E+08 3.90E+07 2.00E+08
03103195 7 3.80E+08 3.70E+08 3.50E+08 3.50E+08
pH V/3LUE
03/07/95 11 8.96 8.94 688 6.7
OXONE OXONE OXONE BLANK
3 4 5 0
6.00E+01 1.00E+00 < 1.00E+00 4.80E+04
1.00E+04 < 1.00E+O0 < 1.00E+00
3 50E+08 < 1.00E+00 < 1.00E+00
5.36 4 93 4.48
GRAMS/LITER
URINE PRETREAT INJECTION SYSTEM
FEBRUARY 1995
OXONE CONCENTRATION EVAI IIATIC}N
Urine Pretreatment Injection
System - Microbial Air Sampling
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Internal Correspondence HAMILTONSTANOARD
May 4, 1995
SVME: 3477
Memorandum to: D. Rethke
cc: J Steele, J. Varsik,
From: R. Marsh
Subject: Urine Pretreatment Injection System - Microbial Air Sampling
The purpose of this memorandum is to report the laboratory findings for
the air sampling that was done on the Urine Waste Collection System.
Introduction
There is a valid interest and concern about the microbial air quality within
closed environments. Space vehicles in particular are of a great concern due to
their re-circulated air, the crew is confined within the cabin for the mission
duration, and due to the vehicle's remote location it is without immediate help or
relief. Within a space vehicle, the life support systems could be microbe
generators clue to microbe growth on biological waste materials. This study
examined the microbial content of air at points entering and within the Urine
Waste Collection System. The Urine Waste Collection System studied used
Oxone® as a urine pretreatment to control microbial activity in urine within the
system. The effectiveness of Oxone® as a microbial control agent was
described in SVME 3445.
The study sampled air with a Millipore® All-Glass Impinger at an air flow
rate of 9.2 liters per minute for 10 minute periods. The microbes were collected
in an impingement fluid described by Millipore® that was assayed for microbial
content using R2A media. The air sampling points were: 1 - at the funnel entry
of the system, 2 - between the urine separator and the filter, and 3 - at the air
outlet after the filter.
Results
The results of the study showed that the sample points within the system
and at the system air outlet did not contain microbes over the detection limits of
12 CFU per M _. The air sampled at the funnel entry point showed that the room
air entering the system contained 193 CFU per M 3. The recovered
microorganisms were of several different types.
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Sample Point Result
System Inlet
Between Separator & Filter
After urine collection
After water flush
System Outlet
193 CFU/M 3
<12 CFU/M _
<12 CFU/M 3
<12 CFU/M 3
Conclusion
These results indicate that the Urine Waste Collection System using
Oxone® as a urine pretreatment for microbial control does not add microbes to
the effluent air over the environmental back ground within the time frame of this
test. The Oxone® pretreatment was demonstrated to be an effective microbial
control as described in SVME 3445. In this testing, there were no microbes
recovered over the detection limits from the air within or exiting the Urine WCS
system.
Prepared by: '_-_Z_ _'(
Robert W. Marsh
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